

# Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls.

Birte Kristensen

This review has been accepted as a thesis together with three previously published papers by the University of Southern Denmark on 15<sup>th</sup> of October 2014 and defended on 24<sup>th</sup> of April 2015.

Tutor(s): Laszlo Hegedüs, Claus H Nielsen & Terry J Smith

Official opponents: Petros Perros, Bjarne Kuno Møller & Torben Barington

Correspondence: Department of Endocrinology and Metabolism, Odense University Hospital, 5000 Odense, Denmark.

E-mail: birte.k85@gmail.com

Dan Med J 2016;63(2):B5177

## The three original papers include:

1. Langkjær A, Kristensen B, Hansen BE, Schultz H, Hegedus L, Nielsen CH. B-cell exposure to self-antigen induces IL-10 producing B cells as well as IL-6- and TNF- $\alpha$ -producing B-cell subsets in healthy humans. *Clin Immunol* 2012; 145: 1-10.
2. Kristensen B, Hegedüs L, Lundy S, Brimnes MK, Smith TJ, Nielsen CH. Characterization of Regulatory B cells in Graves' Disease and Hashimoto's Thyroiditis. *PLOS One* 2015; 10: e0127949.
3. Kristensen B, Hegedüs L, Madsen HO, Smith TJ, Nielsen CH. Altered balance between self-reactive Th17 cells and Th10 cells and between full-length FOXP3 and FOXP3 splice variants in Hashimoto's thyroiditis. *Clin Exp Immunol* 2015; 180: 58-69.

## Introduction Autoimmunity

Autoimmunity is the breakdown of immune self-tolerance (1) and can occur in an organ-specific or systemic manner. Organ-specific autoimmunity is characterized by a T-cell or antibody mediated attack on a specific organ, whereas systemic autoimmunity is an uncontrolled immune response towards ubiquitous self-antigens (1,2). Under homeostatic conditions, central and peripheral tolerance aid in eliminating auto-reactive T and B cells. While in the thymus or bone marrow, T cells and B cells, respectively, undergo checks to determine their self-reactivity (3). Central tolerance is the elimination of auto-reactive T cells and B cells, in the thymus and bone marrow, respectively; it recognizes self-antigens with a strong affinity (2,4,5). The main mechanism of central tolerance is negative selection. Negative selection allows the elimination of developing T cells and B cells if the corresponding receptor on T cells (TCR) or on B cells (BCR) recognizes a self-antigen with high affinity (4–7). Additionally, B cells undergo receptor editing to avoid deletion. Receptor editing is the re-arrangement of

genes that encode the BCR and thus allow the expression of a BCR with low affinity towards self-antigens (5,8). T cells and B cells that are able to recognize self-antigens with a low affinity are able to leave the thymus and bone marrow, respectively (5). At this point, peripheral tolerance including anergy as well as regulatory T cells and B cells steps in and aids in the regulation of auto-reactive cells (9–13).

## Human T lymphocytes

Within the T cell group, multiple subsets exist, including CD4+ T helper (Th), CD8+ cytotoxic T cells (CTL), natural killer T cells (NKT cells) and regulatory T cells (Tregs) (14). All these subsets play an important role within the immune system. However, only CD4+ T cells and regulatory T cells will be discussed here.


## Th1 / Th2

To stimulate a naïve CD4+ T cell (Th0), both the TCR and the co-stimulatory molecules are needed to be stimulated. This occurs by interaction between antigen presenting cells (APC) and Th0 cells (14). However, it is the local cytokine milieu that will determine whether a Th0 cell will become a Th1 or a Th2 cell (14–16). Figure 1 summarizes the differential pathways of a naïve CD4+ T cell. It was Mosmann et al that initially coined the term 'Th1 and Th2' (17,18). Classically, Th1 cells will produce interferon-gamma (IFN- $\gamma$ ), tumor necrosis factor-alpha (TNF- $\alpha$ ), and interleukin-2 (IL-2), whereas Th2 cells are known to secrete IL-4, IL-5, IL-10, and IL-13 (15,17–20). The presence of IL-12 and IFN- $\gamma$  will activate signal transducer and transcription activator 4 (Stat4) and Stat1 signalling pathways, respectively, which induces T-bet expression, thus promoting Th1 cellular differentiation (21–23). For Th2 differentiation, exogenous IL-4 induces GATA3 via the Stat6 signalling pathway (22,24,25). IL-2 acting via Stat5 signalling pathway is also needed for full Th2 differentiation (22,26).

Once fully differentiated, IFN- $\gamma$  and IL-4 are needed to amplify and augment pre-existing Th1 and Th2 cellular populations, respectively (15,22,27). This will allow for a Th1 or Th2 dominated immune response. It is known that Th1 and Th2 cells can cross-regulate each other and that this cross-regulation can occur on a cytokine and transcriptional level (22). IFN- $\gamma$  secreted by Th1 cells can suppress the expansion and effector function of Th2 cells. Additionally, IL-4 produced by Th2 cells can exert the same regulatory function on Th1 cells (15,22,28). On a transcriptional level, T-bet can suppress Th2 differentiation by preventing GATA3 from binding to the Th2 cytokine gene locus and inhibit cytokine production, which would lead to Th2 differentiation (22,29). On the other hand, GATA3 has been shown to downregulate Stat4, which is crucial for Th1 development (22,30). One study by Usui et al has

suggested that Th1 differentiation occurs because T-bet suppresses GATA3 instead of amplifying the IFNG gene (31).

Th1 and Th2 cells are functionally distinct. Where Th1 cells aid in the combat of intracellular bacteria, such as mycobacterial infections, and viruses, Th2 cells help with extracellular parasites such as helminths (15,18,20,22,23). However, if these responses are not regulated, exaggerated Th1 responses have been linked with several organ-specific autoimmune diseases and exaggerated Th2 responses have been shown to play a crucial role in the development of allergic inflammation and asthma (20,32).



**Figure 1** Summary of the differentiation pathways of a naïve CD4+ T cells.

### Th17 cells

The discovery of a third Th subset, namely Th17, caused a shift in the classical Th1 and Th2 paradigm. The third Th cell subset is termed 'Th17' due to its ability to produce the cytokine IL-17A and IL-17F (33,34). These cells also produce IL-21, IL-22, and IL-26 (35). IL-17 is thought to be a pro-inflammatory cytokine that is able to induce local inflammation by stimulating the production of IL-6 as well as amplifying local inflammation by synergizing with other pro-inflammatory cytokines such as IL-1 $\beta$ , IFN- $\gamma$  and TNF- $\alpha$  (36). The cytokines produced by Th17 cells have effects on numerous immune and non-immune cells, some of which include epithelial cells, NK cells, B cells, macrophages, and neutrophils (35). The primary function of Th17 cells is to provide protection to the host by aiding in the clearance of extracellular bacteria and fungi (37). However, Th17 cells have also been linked to various autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease, multiple sclerosis, and autoimmune thyroid disease (38–41).

The differentiation of human Th17 cells from Th0 cells is still unclear. Several cytokines including IL-1 $\beta$ , IL-6, IL-21, IL-23, TNF- $\alpha$  and transforming growth factor-beta (TGF- $\beta$ ) have been involved in the differentiation of human Th17 cells either in combination or alone (42–46). The exact effect of IL-23 on human Th17 cells is not yet clear. In mice, it is known that IL-23 is upregulated only after cellular activation (33) and may have a role within Th17 expansion and pathogenicity, but in humans its central role may only be to direct Th17 differentiation (16,46).

The role of TGF- $\beta$  in Th17 differentiation is truly fascinating. Until recently, TGF- $\beta$  has been associated with regulatory T cells (Tregs) and not Th17 differentiation. Several groups have reported that TGF- $\beta$  is crucial to Th17 differentiation (42,44,46,47). However, TGF- $\beta$  may not have a direct role in Th17 differentia-

tion, but instead it may limit Th1 differentiation and thereby allow the differentiation of Th17 cells (48). Further investigation is needed to clarify the role of TGF- $\beta$  in Th17 differentiation.

Human Th17 cells express the transcription factor retinoic acid receptor-related orphan receptor C (RORC) (49,50), which distinguishes these cells from the prototypical Th1 and Th2 cells (51). RORC is the human ortholog to the mouse ROR $\gamma$ t (37). The cytokines IL-1 $\beta$ , IL-6, IL-23, and TGF- $\beta$  are all able to induce the expression of RORC in Th17 cells (37,44,45,52).


### Regulatory T cells

Tregs are crucial in maintaining homeostasis within the immune system (13). Tregs help to prevent an immune response against self-antigens as well as to suppress an immune response against exogenous antigens before they can become a danger to the host (10,53). Regulatory T cells consist of a heterogeneous population of cells including CD4+ T cells, CD8+ T cells and NK cells (54). However, only natural and inducible Tregs which are CD4+ will be discussed here.

Natural Tregs (nTregs) are developed in the thymus and migrate to the periphery (54). These Tregs are characterized by the surface markers CD4, CD25 (9), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and glucocorticoid-induced tumor-necrosis-factor-receptor-related protein (GITR) (54,55). Additionally, the transcription factor, forkhead box protein 3 (FOXP3), is important in the identification and development of nTregs (56–58). The cytokine TGF- $\beta$  is reportedly able to enhance the expression of FOXP3, and is thus vital in the maintenance of nTregs (54). The specificity of the TCR on nTregs is towards self-antigens that are present in the thymus (53). This allows nTregs to suppress auto-reactive T cells and B cells by cell-contact dependent mechanisms (53,59), and one of the core methods of suppression is the expression of CTLA-4. CTLA-4 regulates the co-stimulatory markers CD80/CD86 (59–61) and by binding to CD80/CD86, CTLA-4 gives the inhibitory signals which will prevent T cell activation (59,61). Normally, CD80/CD86 binds to CD28 and provides the necessary co-stimulatory signals to allow for T cell activation (62). In addition, nTregs may act like a 'sink' for the available IL-2 in the micro-environment, which will result in the apoptosis or downregulation of effector T cells. This is because IL-2 is needed for effector T cell survival and growth, but also for the activation of nTregs and the upregulation of FOXP3 expression (54,59,63–65).

Inducible Tregs (iTregs), also known as adaptive Tregs, differentiate from effector (CD4+CD25-) T cells into iTregs in the periphery (10,53,66). iTregs are identified based on their ability to secrete IL-10 and TGF- $\beta$  (10,67,68). There is speculation that iTregs are not one heterogeneous population, but are sub-divided into two populations named Tr1 and Th3, the difference being the cytokines that they secrete. Tr1 cells are thought to secrete mainly IL-10, whereas Th3 cells secrete predominately TGF- $\beta$  (66,69). The conversion of effector (CD4+CD25-) T cells into iTregs is achieved after antigen recognition and with help from CTLA-4, TGF- $\beta$  or IL-10 (54,68,70–72) and after stimulation through CD46 (73). Unlike nTregs, the suppression method for iTregs is cytokine dependent and is carried out via the secretion of IL-10 and TGF- $\beta$  (10,53,70,72). The suppressive effects of IL-10 and TGF- $\beta$  are multifaceted. Indirectly, iTregs, via IL-10 and TGF- $\beta$ , can affect the function, cytokine production, and co-stimulatory molecule expression of APC, which would subsequently affect the cytokine production and proliferative capability of CD4+ T cells. Directly, iTregs, via IL-10 and TGF- $\beta$ , can affect the cytokine production of CD4+ T cells (74–78)(10,68). Although, the main suppressive mechanism of iTregs is cytokine-dependent, there is some data

that indicate that iTregs may upregulate inhibitory receptors that could inhibit APC or CD4+ T cells on a cell-to-cell contact basis (10,53).



**Figure 2** Regulatory T cell subsets.

Difficulty arises when trying to discern nTregs from iTregs or even from effector (CD4+CD25-) T cells, due to the similarities in the expression of certain surface markers. iTregs have been shown to acquire the expression of CD25 and FOXP3 (79), while nTregs, normally cytokine independent, can induce and secrete IL-10 and/or TGF-β (80–82). Studies have also demonstrated that effector (CD4+CD25-) T cells in the periphery can acquire the expression of FOXP3 and CD25, as well as regulatory T cell activity (83–86).

The transcription factor FOXP3 is a key component in the suppressive function, development, and cell lineage commitment of regulatory T cells (56–58). Mutations in FOXP3 may lead to dysfunction of or a lack of Tregs. If this occurs in humans, the condition called immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome may arise, which includes uncontrolled cytokine production and proliferation (87,88). However, recent evidence suggests that there are three isoforms of human FOXP3. These three isoforms are full length FOXP3 and the two truncated splice forms: FOXP3Δ2, which lacks exon 2, and FOXP3Δ2Δ7, which lacks exons 2 and 7 (89–91). It is not known whether these FOXP3 isoforms are co-expressed or are expressed in different Tregs, but it is conceivable that all three isoforms are functionally different. Full length FOXP3 functions as a repressor of NF-κB, NF-AT, RORγt and ROR-α (92–96). However, FOXP3Δ2 isoform is unable to functionally repress RORγt (95), ROR-α (94), and NF-κB (96,97).

### Th17 and Treg plasticity

Human Th17 cells are potentially not locked into one phenotype but are able to exhibit plasticity. Annunziato et al were among the first to show that a proportion of human Th17 cells were able to produce both IL-17 and IFN-γ; they are called the ‘Th17/Th1 cells’. In the same study, they also showed that human Th17 cells were able to differentiate into Th1-like cells and produce IFN-γ in the presence of IL-12 (98). These cells were called ‘non-classical Th1’ or ‘Th17-derived Th1 cells’. The expression of the IL-12 receptor is important for the differentiation into Th1 cells (98,99). Additionally, depending on the stimulation Th17 cells can produce IFN-γ or IL-10. Zielinski et al showed that stimulating with *Candida albicans* Th17 cells were able to produce IL-17

and IFN-γ, while stimulating with *Staphylococcus aureus*, Th17 cells were able to produce IL-17 and IL-10 (100).

In addition to Th17 cells having the ability to exhibit plasticity, there is a growing notion that Tregs can also exhibit plasticity. It has been demonstrated that CD4+CD25hi Tregs can express the transcription factors FOXP3 and RORγt, concurrently (101,102). These CD4+CD25hiFOXP3+ Tregs have also been shown to produce IL-17 after PMA/ionomycin stimulation with or without IL-1β and IL-6 present (101–104). The presence of pro-inflammatory cytokines, such as IL-1β and IL-6, might enhance IL-17 production in FOXP3+ Tregs. This might be important at sites of inflammation or in autoimmune diseases where these pro-inflammatory cytokines are in abundance. However, there are conflicting results as to whether or not these IL-17+FOXP3+ Tregs lose their suppressive function after secreting IL-17. Voo et al demonstrated that IL-17+FOXP3+ Tregs are still capable of inhibiting proliferation of CD4+ T cells, whereas Beriou et al observed a diminished suppressive activity of IL-17+FOXP3+ Tregs in terms of inhibiting IFN-γ production (103,104). A closer and more complex relationship between CD4+CD25hi Tregs and Th17 cells could exist than initially thought.

### Human B lymphocytes

Human B cells are developed in the bone marrow from hematopoietic stem cells (105) and have multiple functions within the immune system. They are able to produce antibodies, cytokines, and function as antigen presenting cells (106–109). B cell subsets, such as B1 B cells, transitional B cells, marginal zone B cells, and follicular B cells, have been more extensively investigated in mice than humans. Therefore, what is currently known about B cell subsets in mice and humans is summarized below.

#### B1 B cells

In mice, B1 B cells are located in the peritoneal and pleural cavities (110,111) and are able to spontaneously produce natural antibodies that provide the first line of defense against pathogens (14,112,113). Additionally, these B1 B cells are self-replenishing (110,114) and are able to efficiently present antigens and induce differentiation of effector CD4+ T cells (115). In mice, B1 B cells are comprised of two subsets, B1a and B1b, and these subsets are defined on the basis of CD5 expression (105,110,114). Similarly, in humans, CD5+ B cells play a protective role in the host by the production of natural antibodies (116,117). In several autoimmune diseases, such as RA and systemic lupus erythematosus (SLE), it has been observed that patients have an increased frequency of CD5+ B cells and that these B cells are able to produce autoantibodies (118–120). However, the existence of B1 B cells and use of CD5 as a phenotypic marker in humans is still under great debate. CD5 is expressed on the majority of B cells during childhood as well as being used a pan-T cell marker (121,122). It has also been speculated that CD5 is an activation marker and that the expression of CD5 can be induced or upregulated after stimulation with phorbol esters - making it unsuitable for the identification of a distinct cellular subset (116,123). It has been proposed that the human B1 subset can be identified by the phenotype CD19+CD27+CD43+ instead of CD5+ (124). Similar to their murine counterparts, these human B1 B cells are able to spontaneously produce IgM as well as induce stimulation of T cells (124).

#### Transitional B cells

The term transitional B cells was first coined in mouse studies by Carsetti et al (125) and describes B cells that are developmentally situated between immature B cells in the bone marrow and

fully mature B cells in the peripheral blood (126). In mice, transitional B cells have been divided into IgMhiCD21negCD23negIgDneg transitional 1 (T1) or IgMhiCD21hiCD23hilgDhi transitional 2 (T2) B cells (122,127). The expression of the developmental marker, CD23, highlights the difference in the development between the two subsets (128). These CD23hi T2 subsets are located primarily in the spleen and are more capable than T1 B cells in terms of proliferating, differentiating and surviving BCR-induced activation, thus allowing for development into mature B cells (128–131). T1 B cells are located in the bone marrow, blood and spleen and readily die via apoptosis after BCR-induced activation. It has also been suggested that T1 B cells are the precursors for T2 B cells. However, T1 B cells may also develop directly into mature B cells (130).

In humans, earlier observations characterized transitional B cells, located in the peripheral blood or bone marrow, as CD19+CD24hiCD38hi using the two developmental markers CD24 and CD38 (122,131). Additionally, studies have shown that the human bone marrow has a greater proportion of B cells expressing the CD24hiCD38hi transitional phenotype, and that these transitional B cells were able to reconstitute the peripheral blood after hematopoietic stem cell transplantation (126,132). However, more recent studies have indicated that humans, like mice, have two subsets of transitional B cells, namely T1 and T2 (133,134). Human T1 and T2 transitional B cells have been subdivided based on the low or high expression of CD21 or IgD (126,134). The difference in the expression of CD21 or IgD may indicate a difference in the developmental stage of the transitional B cells (126,134). Similar to CD23 in mice, CD21hi T2 B cells in humans are better at proliferating and secreting immunoglobulins than CD21low T1 B cells, indicating that T2 B cells are more developmentally mature than T1 B cells (134). Additionally, human T1 B cells are more prone to apoptosis than T2 B cells, which is comparable to their murine counterpart (131).

### Marginal zone and Follicular B cells

Marginal zone (MZ) and follicular zone (FO) B cells are two subsets of the splenic B cell subset (135), which may be derived from transitional T2 B cells (136). MZ B cells are located in the marginal zone of the spleen whereas FO B cells are primarily located in the lymphoid follicles of the secondary lymphoid organs (111,136,137). In mice, the phenotype for MZ B cells is IgMhigD-lowCD21hiCD23low whereas for FO B cells it is IgMlowIgDhiCD21intCD23hi (138). FO B cells are able to circulate, capture and present T cell-dependent antigens to CD4+ T cells present in the lymphoid follicles in the white pulp (111,136). Additionally, FO B cells may have a role in the production of IgM antibodies in a T cell-independent manner in the bone marrow. This indicates that FO B cells may reside in both the spleen and bone marrow and carry out different functions (111,136,139). MZ B cells are able to rapidly produce antibodies against T cell-independent antigens, such as bacterial antigens, making these cells crucial as the first line of defense against blood-borne pathogens (14,137). In a similar way to FO B cells, studies have shown that MZ B cells can capture and present T cell-dependent antigens to CD4+ T cells and induce antigen-specific differentiation and proliferation (111,138,140). It has been proposed that MZ B cells are more capable of presenting antigens to T cells than FO B cells due to their high expression of co-stimulatory molecules (111,138,140). Another important function of MZ B cells is the shuttling of antigens from the marginal zone to the lymphoid follicles in the spleen. MZ B cells were initially thought of as being sessile however, a study by Cinamon et al demonstrated that MZ

B cells are able to pick up antigen and transport it to the follicles in the spleen (141,142). In humans, MZ B cells have been found and may exhibit similar functions as their murine counterparts. There is evidence that human MZ B cells are important in processing and presenting T cell-independent antigens and providing first line of defense (143). Tables 1 summarizes the different B cell phenotypes discussed in this thesis, and are associated with B1 B cells, transitional B cells, MZ, and FO B cells as well as regulatory B cells.

**Table 1** Summary of B cell phenotypes associated with different B cell subsets.

B cell subset	Possible Phenotypes	
	Human	Mice
B1	CD27+CD43+	B1a: CD5+ B1b: CD5-
Transitional	CD24hiCD38hi T1: CD21low T2: CD21hi	T1: IgMhiCD21negCD23negIgDneg T2: IgMhiCD21hiCD23hilgDhi
Marginal		IgMhigDlowCD21hiCD23low
Follicular		IgMlowIgDhiCD21intCD23hi
Potential Breg cells	CD5+, CD25hi, TIM-1+, CD27+CD43+, CD27+CD43+CD11b+, CD24hiCD27+, and CD24hiCD38hi	

### Regulatory B cells

It has long been believed that B cells may have a suppressive capacity. In the murine model for multiple sclerosis, namely experimental autoimmune encephalomyelitis (EAE), Wolf et al have demonstrated that mice deficient in B cells due to a genetic fault have a greater degree of disease severity and suffer from chronic EAE (144). What role these B cells play in the pathogenesis of EAE was unclear until Fillatreau et al demonstrated that murine B cells were capable of producing IL-10. It was precisely the production of IL-10 that suppressed the Th1-type/pro-inflammatory responses and allowed the EAE mice to recover, proving that B cells did have a regulatory function (11,145). A regulatory role for B cells and IL-10 has subsequently been demonstrated in other murine models of intestinal inflammation (146,147) and autoimmunity including collagen-induced arthritis, a model for RA (148,149). In murine studies, IL-10 produced by murine B cells are able to suppress Th1 and Th17 cells, thereby reducing the production of pro-inflammatory cytokines and responses (147–149). In a study by Carter et al, IL-10-producing B cells were actually capable of inducing iTregs (149).

The existence of regulatory B cells (Bregs) has also been demonstrated in humans. In some studies, Bregs may also be called B10 cells; however, these B10 cells normally denote IL-10-producing B cells. Currently, no one particular surface marker or transcription factor has been pin-pointed to identify Bregs. Therefore, the ability to produce IL-10 is the best marker to date. Several phenotypes have been proposed to identify Bregs, but currently there is no consensus. Some of the prevailing phenotypes include CD5+, CD25hi, TIM-1+, CD27+CD43+, CD27+CD43+CD11b+, CD24hiCD27+, and CD24hiCD38hi (121,124,150–161). A suppressive quality, in terms of inhibiting cytokine production, proliferation or differentiation, has also been demonstrated in human Bregs. Human CD24hiCD27+ Bregs have the ability to inhibit pro-inflammatory cytokine production such as TNF- $\alpha$  and IFN- $\gamma$  from monocytes and CD4+ T cells, respectively, in an IL-10-dependent manner (154,156). Predominately human B10 cells with the phenotypes CD25hi, TIM-1+, CD24hiCD27+ and CD24hiCD38hi, have been shown to suppress

CD4+ T cell activation or proliferation as well as inhibit differentiation of naïve CD4+ T cells into Th1 or Th17 cells (151,157,158,161,162).

Additionally, a number of phenotypic subpopulations such as CD24hiCD27+ and CD24hiCD38hi have been able to convert effector (CD4+CD25-) T cells into Tregs (CD4+CD25hi) with an intact functional suppressive capacity (158–160). Kessel et al demonstrated that CD19+CD25hi Bregs were able to enhance the expression of FOXP3 and CTLA-4 in Tregs. However, this was not dependent on IL-10 but instead partially dependent on TGF- $\beta$  and cell-to-cell contact (157). Intriguingly, Bregs have also been shown to inhibit TNF- $\alpha$  production from CD4+ T cells via an IL-10-independent pathway (156). This contributes to the theory or speculation that Bregs may induce suppression via cytokine-independent methods.

In summary, this indicates that B10 cells may have multiple phenotypes and may have an array of suppressive activities. Currently, there is no definitive B10 cell phenotype (see appendix I for a table reviewing some of the current Breg/B10 literature).

### **Autoimmune thyroid disease**

Autoimmune thyroid disease (AITD), which encompasses Hashimoto's thyroiditis (HT) and Graves' disease (GD), are classical examples of organ-specific autoimmunity (2). These two diseases are clinically diverse because GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism, whereas in HT, T cells aid in the destruction of the thyroid epithelial cells (thyrocytes) and thyroid epithelial structure leading to hypothyroidism (2,163–165). However, these diseases still share several immunological features. These features include lymphocytic infiltration of the thyroid gland as well as auto-reactivity against three thyroid auto-antigens which are thyroglobulin (TG), thyroid peroxidase (TPO) and TSHR (166,167). Figure 3 outlines the immuno-pathogenesis of HT and GD.

### **Clinical diagnosis of GD and HT patients**

Diagnosing GD or HT is dependent on measuring the levels of thyroid stimulating hormone (TSH), serum freeT4 (FT4) and freeT3 (FT3) as well as measuring the autoantibody levels against TSHR and TPO. Individuals diagnosed with GD have suppressed levels of TSH with elevated levels of FT4 and/or FT3 along with elevated anti-TSHR antibody levels. An ultrasound of the thyroid demonstrating diffuse hypoecchogenicity can be used to confirm the GD diagnosis (168). The presence of suppressed TSH, but normal FT4 or FT3 may indicate subclinical hyperthyroidism (169). In contrast to GD, HT patients have a raised TSH level, a decreased level of FT4 or FT3 and the presence of anti-TPO Ab and/or anti-TG Ab (165,170). If HT patients have a raised serum TSH level, but normal FT4 level, that indicates subclinical hypothyroidism (165). Approximately 95% of all HT patients have anti-TPO antibodies and about 60-80% of HT patients have anti-TG antibodies (170). The presence of anti-TPO Abs is a clinical marker for HT, while anti-TSHR Ab is a clinical marker for GD (170,171). However, anti-TPO Abs and anti-TG Abs are not unique to HT patients because these antibodies are detectable in the majority of GD patients (168).

### **Epidemiology, genetic and environmental factors of GD and HT patients**

Both GD and HT are among the most common autoimmune diseases (168,170). Approximately, 2% of the general population

will develop either GD or HT (172,173). In Denmark, the prevalence of female HT patients was 0.4% (174) whereas the prevalence for female GD patients was 1.2% (175) These diseases have a strong female preponderance, which could in part be due to the hormone estrogen (164,176). Parity, the number of times a woman has given birth, and skewed X-chromosome inactivation can help to explain the predominance of GD or HT in females (176,177).

GD and HT are complex diseases caused by a combination of genetic and environmental factors (173,174,178,179). Few susceptibility genes have been discovered and can roughly be divided into immuno-regulatory (HLA-DR, CTLA4, CD40, PTPN22, CD25, and FOXP3) and thyroid-specific genes (TSHR and TG) (164,168,171,176,180,181). However, not all of these susceptibility genes are a causative factor for both GD and HT development because the susceptibility genes CD25, CD40 and TSHR are specific only for GD patients (181). The environmental factors such as dietary iodine, stress, smoking, and alcohol have all been associated with autoimmune thyroid disease (176). Stress or having a stressful daily life may be a risk factor for developing GD, but surprisingly, not for the development of HT (176). In Denmark, iodine was added to table salt and bread in order to prevent country-wide iodine deficiency. As a result of iodine fortification in Denmark, the incidence of hypothyroidism increased, but the prevalence of hyperthyroidism remained the same (182–185). It has been speculated that smoking is associated with the development of AITD (186). Studies from Denmark have shown that cigarette smoking has a protective effect for development of HT/hypothyroidism, but is a risk factor for GD development (173,187,188). Surprisingly, Danish population-based case-control studies have revealed that alcohol may have a protective effect and prevent the development of GD and HT (189,190). However, the mechanisms by which these environmental factors drive AITD pathogenesis is still not clear.


### **Graves' disease**

As mentioned earlier, GD is an autoantibody-mediated disease and often, but not always, is lymphocytic infiltration present in GD patients (167,191). However, the lymphocytic infiltration detected in GD patients may not be as severe as HT or destroy the thyroid architecture (192). In GD, the lymphocytic infiltrate consists mainly of CD4+ and CD8+ T cells as well as CD19+ B cells. As a result of this lymphocytic infiltration into the thyroid gland, ectopic germinal centers (GC) can be formed (191,193). These ectopic GC are secondary lymphoid follicles, which contain autoreactive B cells and allows the affinity maturation of autoreactive B cells. This can potentially lead to the production of autoantibodies (2,194,195). GC might be the source of autoantibodies in the pathogenesis of GD as well as HT.

It is a well-known fact that pathognomonic antibodies are produced against the TSHR in GD, which leads to the over-activation of the thyroid gland and hyperthyroidism (168,196). These TSHR autoantibodies, also called TRAb, primarily belong to the immunoglobulin (Ig) G subtype (197). The types of TSHR auto-antibodies includes thyroid stimulatory (TSAb), TSH blocking (TBAb) and neutral auto-antibodies, which all are regarded to have different biological activity (196,198–200). For example, TSAb will bind and stimulate the TSHR, which induces proliferation as well as increases the thyroid hormone production and consequently leads to hyperthyroidism. Conversely, TBAb, will lead to hypothyroidism because these autoantibodies block the TSHR and reduce thyroid hormone production (198,199,201). The exact function of the neutral TSHR autoantibodies is not yet clear since it seems to

neither stimulate nor block the TSHR (196). The TSHR belongs to the G-protein coupled receptor family and is made up of an ecto-domain subunit A and a transmembrane subunit B (164,201). Uniquely to the TSHR, this receptor undergoes intramolecular cleavage in the ectodomain resulting in the shedding of the subunit A (196,201). It has been suggested that the 'free or shed' subunit A is the immunogen that induces the production of TSHR autoantibodies by B cells (163,202,203). This is because recent studies have shown that monoclonal TSHR Abs of both human and murine origin have a higher affinity towards the 'free or shed' subunit A rather than the holoreceptor (202,203).

Human CD4+ T cells may have several roles within GD pathogenesis. Firstly, the interaction between CD4+ T cells and auto-reactive B cells is required for the production of autoantibodies against the TSHR (2,107,108,164,200). Secondly, CD4+ T cells produce cytokines, predominately Th2-related, including IL-4, IL-5 and IL-10, which may play a protective role in GD (192,204–206). Production of IL-4 and IL-10 may prevent thyrocyte destruction by inducing T cell anergy, preventing IFN- $\gamma$  production by macrophages, inhibiting cytotoxic responses from CD8+ T cells, and by inducing a phenotypic switch from Th1 to Th2 (2,207,208). IL-4 and IL-10 may also up-regulate the expression of anti-apoptotic proteins from the BCL-2 family, which includes Bcl-2, Bcl-xL, and cFLIP (192). Expression of these anti-apoptotic proteins in thyrocytes hinders the activation of the caspase pathway which induces apoptosis (2,209).



**Figure 3.** The immune-pathogenesis of Hashimoto thyroiditis and Graves' disease (Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev Immunol] (Stassi and De Maria; 2:195–204), copyright (2002) (2)).

### Hashimoto's thyroiditis

Hashimoto's thyroiditis (HT) is primarily a T-cell mediated disease where the thyroid parenchyma is destroyed (210). The human thyroid gland is infiltrated with CD4+ and CD8+ T cells, CD19+ B cells, macrophages, and plasma cells leading to destruction of the thyrocytes, fibrosis, impaired thyroid hormone production and eventually hypothyroidism (2,166,192,210). However, what the initial insult is that causes the lymphocytic infiltration into the human thyroid gland is still unclear.

B cells may play multiple roles within HT pathogenesis. Primarily, auto-reactive B cells in HT could be the predominant source for autoantibodies against TG and TPO. These autoantibodies can be produced in various locations including ectopic germinal centers (194,195,210). Additionally, B cells may act as the

antigen presenting cell, presenting thyroid self-antigens and thus activating naïve auto-reactive CD4+ T cells (8,165). B cells, which also have the ability to produce cytokines, may be a source for cytokines contributing to inflammation (211,212). However, the exact role of B cells in HT pathogenesis remains unclear.

Primarily, HT is characterized by thyrocyte destruction, and the rate at which thyrocytes are destroyed determines the clinical outcome of the disease (2,213). Thyrocyte destruction can occur via three main mechanisms: cytotoxic T lymphocytes, death receptors, and antibodies (2).

The role of T cells in HT pathogenesis is well-established. A murine study by Flynn et al showed that L3T4 (mouse CD4+ T cells) are responsible for the initiation of experimental autoimmune thyroiditis (EAT). In the same study, Flynn et al showed that Lyt-2+ cells (mouse CD8+ T cells) played a cytotoxic role in EAT pathogenesis (214). The present theory is that auto-reactive CD4+ T cells become activated, which induces the migration of both B cells and cytotoxic CD8+ T cells into the thyroid gland (166,215). Cytotoxic T lymphocytes (CTLs) produce cytotoxic granules such as perforin, granzymes (including granzyme B), and proteoglycans (216). The perforin molecule functions by forming a pore in the cellular membrane of target cells, and granzyme B functions by activating pro-apoptotic molecules such as caspases and cytochrome c (2). The presence of CTLs or perforin-secreting intra-thyroidal T cells has been detected among HT patients and could be one of the causative factors for thyrocyte destruction and hypothyroidism (217,218). A study by Ehlers et al demonstrated that TPO- and TG-specific CD8+ T cells are present in the peripheral blood and in the thyroid gland of HT patients. The study further demonstrates that these TPO- and TG-specific CD8+ T cells were able to cause the lysis of target cells in vitro. Given the cytotoxic ability of these TPO- and TG-specific CD8+ T cells, this could be an important mechanism for thyrocyte destruction in HT (219). Additionally, the presence of IFN- $\gamma$  in the local environment may be able to promote the expression of several pro-apoptotic genes as well as increase the activity of caspases 3 and 8 and thus perpetuate thyrocyte destruction (2,209).

The second mechanism for thyrocyte destruction is via death receptors. Death receptors including FAS (CD95) have a cytoplasmic death domain that allows the transmission of the apoptotic signal into the cell (220). There is evidence that thyrocytes from HT patients have the expression of both FAS and FAS ligand (213,221–223). A theory is proposed that thyrocytes from HT patients undergo thyrocyte apoptosis in a suicide or fratricide dependent manner due to the simultaneous expression of FAS and FAS ligand (2,215,221,224). This theory is proposed to be one of the main mechanisms for thyrocyte destruction. The interaction between FAS and FAS ligand will induce apoptosis in the cell carrying FAS. Activation of a cell death receptor also enhances the expression of pro-apoptotic genes such as Bid and Bak, which encourages apoptosis in the thyrocyte (192).

It has been suggested that the pro-inflammatory cytokines IFN- $\gamma$  and IL-1 $\beta$ , are able to enhance the expression of FAS on human thyrocytes, especially in HT patients (192,213,215,221–223,225). It has been theorized that the presence of IFN- $\gamma$  and IL-1 $\beta$  in the thyroid gland of HT patients may induce or upregulate the expression of FAS. This increased FAS expression may perpetuate thyrocyte destruction (222). Evidence has shown that infiltrating T cells among HT patients had low or lacked any significant expression of FAS ligand indicating that infiltrating T cells did not induce thyrocyte destruction (215,222,224,226). However, infiltrating T cells still might play a role in thyrocyte destruction by providing the cytokines IL-1 $\beta$  and IFN- $\gamma$  (222).

The third mechanism of thyrocyte destruction is by autoantibodies. Characteristically, patients with HT have autoantibodies against TG and/or TPO (210). Several studies have shown that autoantibodies, especially IgG1 anti-TPO antibodies, may cause thyrocyte destruction by fixing complement and inducing antibody-dependent cell-mediated cytotoxicity (ADCC) (227,228). As a result, the destroyed thyrocytes will then release cytokines such as IL-6, IL-1 $\beta$ , and IL-8, which can either initiate or perpetuate the inflammation by causing more lymphocytes to migrate to the thyroid gland (2,229,230). Our group has shown that TPO-antibodies promote production of pro-inflammatory cytokines by phagocytic cells and T cells, by facilitating binding of TPO/anti-TPO complexes to Fc $\gamma$ -receptors on antigen-presenting cells (231). However, uncertainty remains as to whether autoantibodies are truly pathogenic or are secondary to the inflammation and destruction occurring in the thyroid gland (232).

It was initially believed that HT was a Th1-mediated disease, and there is ample of evidence to support this theory (233–236). However, recent data is suggesting that Th17 cells may play a more prominent role in HT. In particular, studies by Shi et al, Nanba et al and Figueroa-Vega et al, have shown that HT patients have increased proportions of circulating Th17 cells secreting IL-17, both in the peripheral blood and thyroid gland (39–41). IL-17 is known to be pro-inflammatory and induce the production of other pro-inflammatory cytokines such as IL-1 $\beta$  and IL-6, both of which have a role in HT, and chemokines from neighboring cells (35). Thus, this might perpetuate the inflammation and enhance the migration of lymphocytes into the thyroid gland. IFN- $\gamma$ , which has a critical role in HT, is a key cytokine for Th1 cells. However, IFN- $\gamma$  may also be produced by Th17 cells. There is data to suggest that Th17 cells are able to produce both IL-17 and IFN- $\gamma$  (called Th17/Th1 cells) (98). Additionally, in sites with chronic inflammation, Th17 cells may differentiate into Th1 cells if IL-12 is present (99). Further investigations are needed to determine which Th subset, Th1, Th17 or Th17/Th1, is more important in HT.

### Role of thyroid epithelial cells in AITD

Thyroid epithelial cells or thyrocytes may have a much larger role to play in the pathogenesis of HT and GD than initially thought. Thyrocytes have been shown to express MHC class II which interacts with CD4+ T cells (237). The expression of MHC class II, induced by IFN- $\gamma$ , allows the thyrocyte to act as an antigen presenting cell (237,238). Under normal conditions, the MHC class II expression induces anergy in naïve CD4+ T cells due to the lack of the co-stimulatory molecules CD80/CD86 on the thyrocyte. Therefore, under normal conditions, thyrocytes are able to induce peripheral tolerance (180,239). However, in AITD, auto-reactive memory CD4+ T cells exist and become stimulated and proliferate in response to the auto-antigens presented by MHC class II on the thyrocyte. This will then perpetuate the autoimmune response (180,237). Additionally, thyrocytes, themselves, are able to produce and secrete a whole host of pro-inflammatory cytokines and chemokines. These cytokines and chemokine will stimulate T cells and B cells and increase the migration of lymphocytes to the thyroid gland, thus perpetuating the disease (229,230,240,241). Therefore, thyrocytes may not be the innocent bystander, as once believed, and may, in fact, play an important role in the pathogenesis of AITD.

### Aims of the PhD study

The overall aim of this PhD study is to investigate the pathogenesis of autoimmune thyroid disease with respect to thyroid self-antigens and the effect they have on the immune system.

The specific objectives of this PhD study are:

- To investigate the ability of B cells to present AITD-associated self-antigens including TG and TPO to T cells in healthy donors and AITD patients.
- To determine whether TG and/or TPO could drive a pro-inflammatory or regulatory response in B cells and CD4+ T cells in healthy donors and AITD patients.
- To investigate if there is a difference between healthy donors and AITD patients with respect to B cell phenotypes associated with regulatory B cells.
- To investigate whether the regulatory response is impaired or defective in patients with AITD in comparison to healthy donors.

### Summary of papers I to III

A summary of the findings from all three articles are outlined below.

#### **Paper I: B-cell exposure to self-antigen induces IL-10 producing B cells as well as IL-6- and TNF- $\alpha$ -producing B-cell subsets in healthy humans.**

*Material and Methods:* Peripheral blood mononuclear cells (PBMC) were isolated from 18 healthy donors. Monocytes or B cells were depleted from isolated PBMC using Dynabeads coated with anti-CD14 or anti-CD19, respectively, followed by CFSE labelling. CFSE-labelled intact PBMC or monocyte-/B-cell-depleted PBMC were plated at a density of  $2.5 \times 10^5$  cells per well in a 96-well plate and stimulated with TG (30 $\mu$ g/mL) or TT (30 $\mu$ g/mL) for 7 days. Culture supernatants were collected at day 1 and the cytokines measured were TNF- $\alpha$ , IFN- $\gamma$ , IL-2, IL-4, IL-6, and IL-10 using the Th1/Th2 cytometric bead array kit. Concomitantly, B cells and CD3+ T cells were purified from intact PBMC using Human B cell Enrichment and Human CD3 Positive selection kits, respectively. Purified B cells were preloaded with no antigen, TG (30 $\mu$ g/mL) or TT (30 $\mu$ g/mL).  $1.0 \times 10^5$  TG- or TT-pulsed B cells were co-cultured with  $2.5 \times 10^5$  purified CD3+ T cells for either overnight or 7 days. The cytokines TNF- $\alpha$  and IL-10 were measured using anti-CD45/anti-capture antibody beads, whereas IL-6 was detected using intracellular staining and stained with anti-IL-6 PE antibody.

*Results:* Depletion of monocytes from intact PBMC induced a significant reduction in TNF- $\alpha$ , IL-6 and IL-10 production ( $P < 0.009$ ,  $P < 0.02$ ,  $P < 0.04$  respectively). However, depletion of B cells resulted in a significant reduction of IL-10 only ( $P < 0.05$ ). TG-pulsed B cells, but not TT-pulsed B cells, were able to induce IL-10 secretion in  $1.1 \pm 0.5\%$  of B cells ( $P = 0.01$  versus TT) and  $1.0 \pm 0.2\%$  of CD4+ T cells ( $P = 0.006$  versus TT). Additionally, TG also induced secretion of IL-6 and TGF- $\beta$ . In contrast, TT induced secretion of the Th1-type cytokines IFN- $\gamma$  and IL-2. Both TG- and TT-pulsed B cells induced TNF- $\alpha$  secretion. The IL-10-secreting B cells detected in this study were significantly enriched with the surface markers CD5 ( $P = 0.03$  versus non-IL-10 secreting cells) and CD24 ( $P = 0.02$  versus non-IL-10 secreting cells), and not with CD27 and CD38 surface markers. After 7 days, IL-10 secretion by  $3.3 \pm 1.0\%$  of CD4+ T cells was still observable after co-culture with TG-pulsed B cells. No IL-10 secretion was detected from TG-pulsed B cells on day 7.

*Conclusions:* Our findings show that B cells pulsed with the self-antigen TG is able to induce the secretion of IL-10 in both B cells and CD4+ T cells. Additionally, TG-pulsed B cells also induced the production of IL-6 and TNF- $\alpha$ . Also, higher frequencies of the

IL-10-secreting B cells were CD5+ and CD24hi. Together, TG-pulsed B cells are able to drive a protective immune response.

### **Paper II: Characterization of Regulatory B cells in Graves' Disease and Hashimoto's Thyroiditis.**

**Material and Methods:** Peripheral blood was collected from 12 healthy donors as well as from 12 HT patients and 12 GD patients. For induction of cytokine production,  $1 \times 10^6$  isolated intact PBMC were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin cell stimulation cocktail ( $2 \mu\text{L}/\text{well}$ ) for 4 h. PBMC were stained extracellularly with a combination of the following antibodies: anti-CD19-PerCP, anti-CD5 APC, anti-CD43 FITC, anti-CD27 PECy7, anti-CD24 FITC, anti-CD38 PECy7, anti-CD25 FITC, anti-TIM-1 PE, and intracellularly with either anti-IL-10 APC or anti-IL-10 PE. Concurrently, B cells were isolated and purified using the Human CD19 Positive Cell Isolation kit. Purified B cells ( $1 \times 10^5$  cells) were preloaded with TG ( $30 \mu\text{g}/\text{mL}$ ) or CpG oligodeoxynucleotide (ODN;  $10 \mu\text{g}/\text{mL}$ ) for one hour. The preloaded B cells were co-cultured with  $2 \times 10^5$  of the remaining PBMC for 48 h. The co-cultured cells were stained extracellularly and intracellularly with anti-CD19 APC, anti-CD14 FITC, anti-CD4 PerCP, anti-CD8 PECy7, and anti-IL-10 PE.

**Results:** Among the HT patients, 6.1% and 2.5% of the bulk B cells expressed the surface markers CD25 and TIM-1, respectively, in comparison to 2.9% and 1.6% of the bulk B cells among the healthy donors ( $P=0.026$  and  $P=0.015$  respectively). GD patients did not differ in their frequency of CD25+ or TIM-1+ B cells when compared to healthy donors. No differences were found between each patient group and healthy donors in terms of CD24hiCD38hi and CD27+CD43+ B cells frequencies. However, patients with HT or GD had a lower frequency of CD24hiCD38- B cells than healthy donors ( $P=0.02$  and  $P=0.0005$ , respectively). Additionally, GD patients also had lower proportions of CD27+CD43- B cells ( $P=0.037$  versus healthy donors). The cytokine IL-10 was induced by the polyclonal stimuli PMA/ionomycin and CpG ODN and by the antigen-specific stimulus TG. PMA/ionomycin and CpG ODN induced IL-10 secretion from approximately 1% of B cells. TG induced IL-10 secretion in 0.05% of healthy donor and HT patient B cells as well as in 0.18% of GD patient B cells. No differences were detected in the frequency of IL-10-secreting cells between each patient group and healthy donors after stimulation with PMA/ionomycin, CpG ODN or TG. HT patients had a significantly higher proportion of CD25+ and TIM-1+ B10 cells than healthy donors ( $P=0.0009$  in both cases). Similarly, GD patients also had a significantly higher proportion of CD25+ and TIM-1+ B10 cells than healthy controls ( $P=0.039$  and  $P=0.024$ , respectively). Similarly to bulk B cells, no differences were found in the proportions of CD24hiCD38hi and CD27+CD43+ B10 cells between patients and healthy donors. HT patients had a significantly lower proportion of B10 cells within the CD24hiCD38- subset than healthy donors ( $P=0.012$ ). GD patients had a lower proportion of CD27+CD43- B10 cells than healthy donors ( $P=0.019$ ).

**Conclusions:** Similar frequency of B10 cells are detected in HT, GD and healthy donors indicating that B cells from patients are not impaired with respect to inducing an immuno-regulatory response. The B10 cells did not segregate into any clearly defined subgroups, but HT patients had increased frequencies of CD25+ and TIM-1+ B10 cells.

### **Paper III: Altered balance between self-reactive Th17 cells and Th10 cells and between full-length FOXP3 and FOXP3 splice variants in Hashimoto's thyroiditis.**

**Material and Methods:** This study included blood from 10 HT patients, 11 GD patients and 15 healthy donors. Isolated PBMC were plated onto a 96-well plate with a density of  $5 \times 10^5$  cells per well and stimulated with either TG ( $30 \mu\text{g}/\text{mL}$ ), TPO ( $30 \mu\text{g}/\text{mL}$ ), E. coli LPS ( $50 \text{ng}/\text{mL}$ ), anti-CD3/anti-CD28 or left unstimulated. PBMC were stimulated for a total of 18h to measure IL-17 or IL-6 or for 48h to measure IL-10. PBMC were first extracellularly stained with anti-CD4 PerCP, anti-CD45RA FITC, and anti-CD45RO APC, and then intracellularly stained for either anti-IL-17A PE, anti-IL-6 PE or anti-IL-10 PE. Culture supernatants were assessed for IL-1 $\beta$ , IL-6, and TGF- $\beta$ 1 production by Luminex after 18h. Concurrently, mRNA was extracted, purified and cDNA was synthesized from  $5 \times 10^5$  PBMC after no stimulation or stimulation with TG, TPO, E. coli LPS or anti-CD3/anti-CD28. Subsequently, total FOXP3 and FOXP3 $\Delta$ 2 isoform was measured. As house-keeping gene, CD4 was utilized due to the stability of its expression irrespective of stimulation or not. Additionally, FOXP3 is expressed by CD4, thus it is preferred to use a house-keeping gene that is specific to the cell population studied.

**Results:** After stimulating with the thyroid self-antigen TG, no differences in the frequency of IL-17 producing cells were detected between each patient group and healthy donors in either the naïve or memory Th cell compartments. In contrast, TPO and E. coli LPS induced IL-17 production in 2.8 and 11.9 per 10,000 naïve Th cells among HT patients, but failed to do so in GD patients or healthy donors ( $P=0.016$  and  $P=0.014$  versus healthy donors, respectively). The induction of Th10 cells, was uniform between each patient group and healthy donors, irrespective of whether TG, TPO or E. coli LPS was used as a stimulus. However, compared to healthy donors, a significant reduction in the proportion of IL-10-producing cells were observed among HT patients after anti-CD3/anti-CD28 stimulation ( $P=0.028$ ). After stimulation with TG, naïve Th cells among healthy donors preferentially differentiated towards a Th10 phenotype, whereas the naïve Th cells among patients with HT or GD differentiated towards a Th17 phenotype. HT patients had a higher baseline production of both IL-6 and TGF- $\beta$ 1 than healthy donors ( $P=0.038$  and  $P=0.0096$ , respectively) possibly contributing towards Th17 differentiation. Only in the healthy donor group did stimulation with TG or TPO enhance the IL-6 production above the basal level. In contrast, E. coli LPS induced the production of IL-6 above the basal level in all three groups. Stimulation with TG, TPO or E. coli LPS did not alter TGF- $\beta$ 1 expression in any of the three groups. In addition, the baseline expression of total FOXP3 was uniform in all three groups. However, HT patients as well as GD patients had a higher baseline expression of FOXP3 $\Delta$ 2 than healthy donors ( $P=0.012$  in both cases).

**Conclusions:** An increased frequency of thyroid antigen-specific Th17 cells in the naïve CD4+ T cell compartment is detected in HT patients while the frequency of Th10 cells remains unaltered. This indicates a skewed Th17:Th10 ratio in HT patients. Additionally, an elevated baseline production of IL-6 and TGF- $\beta$ 1 and of mRNA encoding FOXP3 $\Delta$ 2 may contribute to the skew towards Th17 differentiation detected in HT patients.

### **Discussion**

The discussion below will deal with IL-10 production by B cells, regulatory B cell phenotypes, the antigen presenting ability of B cells and monocytes, IL-10 and IL-17 production from CD4+ T cells, Th17/Th10 ratio and Th17 differentiation, and finally FOXP3 and Th17 plasticity.

### **The B cell studies IL-10 production by B cells**



The human cytokine IL-10 is a regulatory cytokine and was initially discovered by Mossman and colleagues who showed that murine IL-10 was able to inhibit cytokine production from Th1 cells (242). The biological activities of IL-10 are far-reaching and have been shown to have immunosuppressive effects on monocytes and macrophages in terms of inhibiting pro-inflammatory cytokine production as well as antigen presentation (74–76,243). Opposed to the effects of IL-10 on monocytes and macrophages, IL-10 has been shown to have immuno-stimulatory effects on human B cells. In this case, IL-10 helps to prevent apoptosis, increases proliferation and enhances antigen presentation by B cells by up-regulating MHC class II expression (74–76).

In our B cell studies, we used the polyclonal stimuli PMA/ionomycin and CpG ODN 2006 (Toll-like receptor 9 ligand) to maximally stimulate the B cells, as well as a more biologically relevant stimulus, the thyroid self-antigen thyroglobulin (TG). The foreign recall antigen tetanus toxoid (TT) was also used.

In paper I, TG was found to be able to induce a significant secretion of the anti-inflammatory cytokine IL-10 in human B cells from healthy donors. This was in contrast to the foreign recall antigen TT, which induced more Th1-type cytokines such as IFN- $\gamma$  and IL-2, and minimal IL-10. It should be noted that TG also induced the secretion of some pro-inflammatory cytokines including IL-6 and TNF- $\alpha$  from B cells in healthy donors. Similarly, in paper II we were able to induce IL-10 secretion after TG stimulation in healthy donors and in patients with GD or HT. Notably, TG induced similar proportions of IL-10 in all three donor groups. Using TG as the stimulus proved that self-antigens can induce IL-10 secretion from healthy donors and patients. This is novel because IL-10 has been predominately induced by polyclonal stimulation, and TG is more relevant to the pathogenesis of AITD. This indicates that self-antigens induce antigen-specific immuno-regulatory responses by B cells, which may play a role in controlling AITD. Additionally, in paper II, the polyclonal stimuli PMA/ionomycin or CpG were used to induce IL-10 secretion. Such polyclonal stimuli are potent and induce the maximum IL-10 secretion by B cells. CpG stimulates B cells by interacting with its receptor TLR9 and activates NF- $\kappa$ B. This is in contrast to PMA/ionomycin, which diffuses across the cell membrane and activates protein kinase C and NFAT (244–247). We demonstrated that IL-10 secretion was similar between each patient group and healthy donors after PMA/ionomycin or CpG stimulation. In contrast to our results, Zha et al observed a significant decrease in the ability of B cells to secrete IL-10 from new-onset GD patients after stimulation with CpG and PMA/ionomycin (156). An explanation for this discrepancy could be that Zha et al divided the GD patients into two groups based on disease status, active disease and euthyroid, and stated that none of the patients were undergoing anti-thyroid drug treatment before blood collection (156). The possible effects of anti-thyroid drugs on our cytokine production will be discussed below, under the limitations section. The observation that patients with GD or HT were equally as capable of secreting IL-10 as the healthy donors, irrespective of whether TG, PMA/ionomycin or CpG was used, indicates that GD or HT patients do not have a defective immuno-regulation by B cells.

The main difference between the observed B-cell production of IL-10 in paper I and II was the amount of IL-10 secreted after TG stimulation. In paper I, we detected IL-10 secretion from  $1.00 \pm 0.5\%$  healthy donor B cells, whereas in paper II we detected IL-10 secretion by  $0.09 \pm 0.1\%$  from healthy donor B cells. In paper II, among patients with GD or HT, we measured  $0.32 \pm 0.5\%$  and  $0.28 \pm 0.8\%$  IL-10 from B cells, respectively. The primary reason for this difference could be the method used to detect IL-10. In

paper I, a cytokine secretion assay was used, whereas in paper II intracellular staining was used. In the secretion assay, the cytokine is retained on the surface of a cell by a capture antibody during a 45 minute secretion phase (248). There is a risk of false positives, if the cell density is too high, which allows a non-secreting cell to be in close proximity to a secreting cell and thus capture its cytokines (248). However, this has presumably not been the case in our study, since the cell density was kept within the recommended cell density for the assay. For intracellular staining, our studies used the stimulation period that lasted from 4 hours to 48 hours with brefeldin A. Brefeldin A is a fungal metabolite, which blocks the transport of proteins from the endoplasmic reticulum to the Golgi (249,250). It has been shown that brefeldin A affects antigen presentation to both CD4+ T cells and CD8+ T cells by inhibiting the presentation of protein by MHC class II and I, respectively (251,252). If B cell production of IL-10 is dependent upon interaction with CD4+ T cells, then inhibition of antigen presentation by brefeldin A (or interaction between other surface molecules on the two cell types) could be the cause of the lower IL-10 production detected in paper II.

A more trivial explanation for the discrepancy between the IL-10 secretions among the healthy donors in papers I and II is the potential contamination of the TG preparation with LPS. It was discovered in paper II that the bought TG preparation was contaminated with LPS. The contaminating LPS was removed and the preparation purified using the Triton X-114 phase separation technique outlined by Liu et al (253). Triton X-114, a non-ionic detergent, was chosen due to its high protein recovery rate and ability to work with small volumes of the TG preparation. Unfortunately, it cannot be determined whether or not the TG preparation used in paper I was LPS contaminated since the first batch, bought several years earlier, was not tested for LPS contamination. It is well known that LPS, which is a ligand for TLR4 (254–256), is able to induce pro-inflammatory cytokines, such as IFN- $\gamma$ , TNF- $\alpha$ , IL-12, IL-1 $\beta$ , IL-8, and IL-4 (243,255,257,258). However, LPS is also able to induce the production of IL-10 and TGF- $\beta$  from monocytes and/or macrophages (243,259,260). These cytokines may have had a bystander effect on our cytokine production from our CD4+ T cells and/or B cells. However, in paper I, both CD4+ T cells and B cells were isolated, purified and co-cultured back together which prevents the bystander effect from the cytokine production from the monocytes.

Although LPS induces cytokine production it is not clear, when reviewing the literature, whether LPS has an effect on human B cells. Within the literature there is consensus that TLR4 is expressed on monocytes and/or macrophages and dendritic cells (255). Several studies have reported that B cells from healthy donors express very little or no TLR4 (261–263). However, some recent studies have reported that TLR4 expression is upregulated on circulating human B cells during inflammatory diseases, such as type 2 diabetes and periodontal disease (264,265). It is postulated that cytokines like IL-4, or the antigen-specific interaction between B cells and T cells, or possibly a combination of the two, allows the upregulation of TLR4 on B cells (266,267). The function of TLR4 on B cells is not yet fully understood, but there is speculation that TLR4 may actually reduce the cells' ability to produce IL-10 (267,268). With regard to paper I, if B cells do not express TLR4 then the LPS from the first TG preparation would not have affected our cytokine production by B cells, or by T cells in the B-cell/T-cell co-cultures. However, the possibility that the first bought TG preparation was LPS contaminated, and that this had an effect on the cytokine production from the B cells cannot be ruled out. In subsequent studies, TG was purified and determined

to be LPS-free to avoid speculation. Therefore, the IL-10 secretion detected in B cells in paper II was solely due to TG stimulation.

Currently, stimuli such as CpG ODN 2006 (TLR9 ligand), LPS (TLR4 ligand), PMA/ionomycin, anti-CD40 antibodies, and anti-IgM antibodies have been reported to induce IL-10 production in human B cells (151,154,159,160,162). It is not known how the different B cell subtypes including naïve, memory or transitional B cells respond to the different stimuli, and if the different stimuli induces different subsets or types of Bregs (269,270). TLRs are important in initiating the innate immune response, which aids in protecting the host against pathogens and act as the first line of defense (245,247,255,271). It has been suggested that TLRs such as CpG/TLR9 or LPS/TLR4 induces 'innate-like' Bregs and thus induces innate-like responses. These 'innate-like' Bregs produce IL-10 and may be important in the first line of defense to reduce excessive inflammation (11,269,270). In contrast, stimulated with anti-CD40 antibodies, CD40L or anti-IgM antibodies may induce more 'acquired type' Bregs, which may play a role in the adaptive immune response (11,269,270). TLRs such as TLR9/CpG may also play a role in the adaptive immune system by inducing the expression of co-stimulatory molecules, cytokines and enhancing the antigen presenting ability of APCs (245,255,272). CpG and anti-Ig antibodies are presumably the optimal stimuli for inducing IL-10 in human B cells since they simultaneously stimulate via TLR9 and the BCR (162,269).

The overall message from our IL-10 and B cell studies is that the thyroid self-antigen, TG, is able to induce IL-10 production in B cells from healthy donors as well as from patients with GD or HT. This finding is novel and may have implications for the pathogenesis of GD and HT.

### **Regulatory B cell phenotypes**

Human B cells may have a regulatory role within the immune system through the production of IL-10 or TGF- $\beta$  (273). There continues to be great interest in phenotyping these potentially regulatory B cells. However, no definitive phenotype has yet been assigned, and the production of IL-10 is still the best functional hallmark or phenotypic marker we have to identify Bregs.

In paper I, the phenotype of the IL-10-producing B cells among healthy donors (also called B10 cells in this thesis) was investigated. It should be noted that the term 'B10 cells' only encompasses the Bregs that produce IL-10, but other Breg subsets may exist (274). In papers I and II, the CD5+ B10 cells did not represent the majority since approximately 75% of the B10 cells were CD5-. However, it should be noted that in paper I, healthy donor B10 cells induced by TG stimulation were more frequently CD5+ than were the non-IL-10 producing B cells. CD5 expression on B cells has been associated with natural antibody production. Certain B cells have the ability to bind to both self and foreign antigens and to secrete poly-reactive antibodies also known as natural antibodies (116,117,275). It has been speculated that these poly-reactive antibody-producing B (PAB) cells are CD5+ (116,275,276). Within the normal immune response, the CD5+ PAB cells and poly-reactive antibodies aid in protecting the host from infections by several mechanism. These mechanism include activating the complement system and forming the lytic complex, by enhancing the phagocytosis of the bacteria and poly-reactive Ab complex by macrophages or by having a direct neutralising effect (112,117,277,278). Additionally, CD5+ B cells and poly-reactive antibodies may play a role in autoimmunity (277). CD5+ B cells have been shown to be the source of autoantibodies against the rheumatoid factor and double-stranded DNA in RA and SLE

patients, hinting towards a pathogenic role for CD5+ B cells (118–120).

There is evidence that disease-associated autoantibodies are somatically hypermutated, whereas poly-reactive antibodies are not (117). The presence of high-affinity autoantibodies against double stranded DNA in SLE, and against TG, TPO or TSHR in AITD indicates that somatic hypermutation is crucial in the development of pathogenic autoantibodies (279,280). There is speculation that poly-reactive antibodies could be the precursors to the high affinity pathogenic autoantibodies (277,279,280).

In paper II, when investigating the whole B-cell population, healthy donors had an increased proportion of bulk B cells expressing CD24hi than GD patients, but this was not the case for HT patients. The surface marker CD24 has been associated with memory B cells (122), which could indicate that GD patients had a lower proportion of memory B cells. When investigating the phenotype of B10 cells our initial findings (paper I) showed that healthy donors had a higher frequency of IL-10-producing B cells expressing CD24hi. This correlated with the findings in paper II where healthy donors had increased proportions of CD24hi B10 cells. Additionally, in paper II we demonstrated that patients with GD or HT had a significantly lower frequency of CD24hi B10 cells than healthy donors. CD24 has been found to have a role in controlling B cell differentiation and maturation, controlling activation-induced B cell responses, and in co-stimulation for CD4+ T cell growth (281–283). In summary, this indicates that B10 cells expressing CD24 are memory cells regulating T-cell function.

Possible B10 surface markers and phenotypes were expanded upon in paper II, including TIM-1+, CD25+, CD24hiCD38hi, and CD27+CD43+. HT patients had a significantly higher frequency of bulk B cells and B10 cells expressing the marker TIM-1 than healthy donors. The function of TIM-1 is in control of CD4+ T cell effector differentiation and responses (284,285). TIM-1 was primarily believed to be expressed only on CD4+ T cells and vital for regulating Th2 responses. However, new insights have revealed that TIM-1 can be expressed on multiple cell types, and that it is able to regulate not only Th2 cells but also Th1, Th17, and Tregs (285–287). In mice, TIM-1 was shown to be expressed on B cells and ligation of TIM-1 induced IL-10 secretion from said B cells (153). A study by Liu et al was among the first to show that human B10 cells were TIM-1+, and that these TIM-1+ B10 cells were able to suppress IFN- $\gamma$  and TNF- $\alpha$  production from CD4+ T cells (161). Given the regulatory function of TIM-1, the expression of TIM-1 on B cells may aid in the secretion of IL-10 as well as in the regulation of auto-reactive T cells in HT pathogenesis.

Similar to TIM-1, HT patients had a higher frequency of bulk B cells and B10 cells expressing the marker CD25 than healthy donors. It should be noted that GD patients had a higher proportion of CD25+ B10 cells but did not have the corresponding expression on bulk B cells. CD25, the alpha chain of the IL-2 receptor (288,289), has been shown to be expressed on human B cells, and is expanded in untreated multiple sclerosis patients (290,291). CD19+CD25+ B cells are able to secrete IL-10 and suppress CD4+ T cell proliferation (157,291). Intriguingly, Kessel et al observed that CD19+CD25+ B cells are able to enhance the expression of both CTLA-4 and FOXP3 in Tregs (157). This indicates that CD19+CD25+ B cells could have some immuno-modulatory/suppressive functions or at least able to enhance immunosuppressive properties in circulating Tregs. In addition, the expression of CD25 on Tregs (CD25hi or CD25++), allows them to be responsive to IL-2 (9). IL-2 is needed for the development of Tregs but also for their suppressive function (59,63). Having a functional IL-2 receptor allows the

Tregs to act like a 'sink' for the IL-2 in the surrounding microenvironment and thereby, prevents the activation and responses of the surrounding T cells (59,64,65,292). It can be speculated that by having an expression of CD25 on B cells, equivalent to Tregs, this may allow the CD19+CD25+ B cells to act like a 'sink' for IL-2 and thereby inhibit the surrounding effector T cells' responses similarly to Tregs. Additionally, expression of CD25 may allow B10 cells to become activated – and regulate the immune response – under circumstances with abundance of IL-2 in the environment, i.e. in presence of activated effector T cells.

It should be taken into consideration that in our data, TIM-1+ and CD25+ B10 cells did not represent the majority of B10 cells; therefore, these markers should not be used to define B10 cells.

In our findings, there were no differences in the proportion of bulk B cells or B10 cells regarding the transitional B cell phenotype CD24hiCD38hi between healthy donors and patients with GD or HT. Our results do not correlate with the findings of Blair et al or Sims et al, who observed that SLE patients had a higher percentage of CD24hiCD38hi B cells than did healthy donors, or with Flores-Borja et al who observed that RA patients had a decreased percentage of CD24hiCD38hi B cells (131,151,158). The B cell phenotype CD24hiCD38hi has been associated with a regulatory function due to its ability to produce IL-10, limit pro-inflammatory cytokine production as well as control Th1 and Th17 differentiation (151,158). CD24hiCD38hi B cells from RA and SLE patients had a lower IL-10 production and were functionally impaired in suppressing Th17 differentiation or production of Th1-related cytokines, respectively (151,158). It should be noted that IL-10 production has also been detected within the CD24intCD38int and CD24hiCD38- B cell phenotypes, indicating that these subsets also have some immunosuppressive capability (151).

The IL-10+ B cells compared to the IL-10- B cells from paper I were not enriched with the surface marker CD27 among healthy donors. Similarly in paper II, no differences were detected in terms of CD27 expression among the bulk B cells or B10 cells in healthy donors or in patients with GD or HT. CD27 in combination with CD43 has been shown to have some regulatory functions. Griffin et al observed that CD27+CD43+CD11b+ B cells were able to secrete IL-10 as well as modulate T cell activation (124,293). However, no differences were detected among the CD27+CD43+ B10 cells between patients and healthy donors. Another phenotype, which might be of importance but was not included in our studies, is CD24hiCD27+. Iwata et al are among the first to demonstrate that B10 cells from healthy donors are found predominantly in the CD24hiCD27+ B cell subpopulation (154). These B10 cells had the ability to suppress cytokine production from monocytes in an IL-10-dependent manner (154). Inhibition of cytokine production may be due to the fact that IL-10 is able to inhibit NF- $\kappa$ B, and NF- $\kappa$ B is crucial for the production of pro-inflammatory cytokines including IL-1 $\beta$ , IL-6, IL-8, IL-12 and TNF- $\alpha$  (294–296). B10 cells with the CD24hiCD27+ phenotype have also been detected among GD patients and allergic asthma patients. However, in these cases a lower proportion of CD24hiCD27+ B cells and an impairment of their suppressive function were detected (156,159). This indicates that CD24hiCD27+ B cells do have a regulatory function, and that a decrease or lack of suppressive function may facilitate disease development. Further investigation of this phenotype is required to determine the potential role it has for AITD pathogenesis.

From our findings it is evident that B10 cells do not express a particular surface marker or separate into one clear subpopulation or phenotype. This correlates with Bouaziz et al who also discovered that B10 cells can be found in multiple subpopulations (162).

Given the complexity of this field, it will not be sufficient to use only surface markers or even IL-10 to characterize regulatory B cells. A combination of phenotype, function and even genetic profile will be needed to truly define a human regulatory B cell (297).

#### **Antigen presenting ability of B cells and monocytes**

Antigen presenting cells (APC) include B cells, monocytes/macrophages and dendritic cells (109,298–300). In paper I, the efficacy of monocytes and B cells to act as antigen-presenting cells were studied. Depletion of monocytes from whole PBMC significantly reduced the secretion of several cytokines such as TNF- $\alpha$ , IL-6, and even IL-10, while B-cell depletion did not have the same effect. With B cell depletion, only a modest reduction in IL-10 was detected. This could indicate that monocytes were a major source of IL-10, TNF- $\alpha$  and IL-6 (74,243,301). Additionally, depleting monocytes dramatically decreased CD4+ T cell proliferation, which was not observed when B cells were depleted. This shows that, in our study, monocytes were more efficient at antigen presentation than B cells. This is in accordance with a study by Beck et al who observed that monocytes were more efficient than B cells at stimulating human CD4+ T cells and are thus a more efficient antigen presenting cell (302). Intriguingly, a study by Constant et al showed that peptides were preferentially taken up by dendritic cells and B cells preferred the uptake of whole proteins (303).

B cells are competent APC in terms of priming CD4+ T cells and may be the predominant antigen-presenting cells under circumstances where the antigen is scarce, due to their ability to up-concentrate antigens on the cell surface via BCR (107,304). In paper I, human B cells were purified and preloaded with the TG antigen and then co-cultured with CD4+ T cells. Subsequently, we were able to measure IL-10 secretion by the co-cultured CD4+ T cells. This indicates that the purified B cells were acting as antigen-presenting cells. A study by Guo et al was the first to demonstrate the existence of TPO-specific B cells and the ability of these B cells to present TPO to T cells, as indicated by the induction of T cell proliferation in murine spleen cell cultures (305). Nielsen et al demonstrated that TG was able to induce proliferation in CD4+ T cells in cultures of human PBMC. The removal of B cells from intact PBMC markedly reduced this proliferation indicating that B cells were acting as antigen-presenting cells in terms of TG presentation (278). In paper I, the TG-preloaded B cells induced a protective response in the CD4+ T cells by the secretion of IL-10. In contrast, B cells preloaded with TT induced a pro-inflammatory response in the co-cultured CD4+ T cells.

In paper III, intact PBMC were investigated instead of purified B cells and CD4+ T cells. Therefore, it could not be determined whether it was the B cells or the monocytes that acted as the main antigen-presenting cell. However, since depleting monocytes had the biggest effect on cytokine production and proliferation, it can be speculated that it was the monocytes that were acting as the main antigen-presenting cells in paper III.

#### **The T helper cell study**

##### **IL-10 production by CD4+ T cells**

In this thesis, IL-10-producing CD4+ T cells are referred to as Th10 cells. The term 'Th10' has been used in the literature to denote all IL-10-producing Th cells irrespective of their origin (306). As mentioned earlier, the biological activities of IL-10 are far-reaching. IL-10 has also been shown to have both indirect and direct effects on CD4+ T cells. Indirectly, IL-10 can inhibit the production of key cytokines such as IFN- $\gamma$  or IL-4 from monocytes or macrophages which could affect Th1 or Th2 differentiation and

response, thus regulating Th1 and Th2 responses via antigen presenting cells (74–76). Studies have shown that IL-10 may also downregulate MHC class II expression as well as co-stimulatory molecules on monocytes/macrophages resulting in an impaired capacity to stimulate T cells (243,307). Directly, IL-10 may also suppress the cytokine production and the proliferation of CD4+ T cells, as well as induce Tregs (74–76).

In paper I, a significantly higher proportion of CD4+ T cells in healthy donors were able to secrete IL-10 after stimulation with the thyroid self-antigen TG than after stimulation with the foreign recall antigen TT. On the other hand, TT induced the secretion of Th1-type pro-inflammatory cytokines and minimal IL-10 secretion. Once again in paper III, TG was able to induce IL-10 secretion above the background within CD4+ T cells from healthy donors as well as in patients with GD or HT.

In paper III, CD4+ T cells were divided into naïve (CD45RA+CD45RO-) or memory (CD45RA-CD45RO+) cell compartments and TPO, a thyroid self-antigen, and E. coli LPS, a foreign control antigen, were used to induce cytokine production. Our data show that TPO and E. coli LPS were able to induce IL-10 production above the background in both CD4+ T cell compartments in healthy donors as well as in both patient groups. In addition, no differences were found in the proportion of Th10 cells between the healthy donors and patients with GD or HT after polyclonal stimulation with anti-CD3/anti-CD28 antibodies. Our findings show that similar proportions of Th10 cells were detected between patients with GD or HT and healthy donors thereby, indicating that patients were not impaired in the ability of inducing a regulatory T-cell response. It should be noted that the Th10 cells detected in our studies may in fact encompass both iTregs and nTregs because our staining protocol did not discriminate between these two subsets. In the literature, there are conflicting results in terms of the frequency of Tregs in AITD patients. Glick et al, who grouped GD and HT as AITD, observed that the frequency of CD4+CD25hi Tregs were similar between AITD patients and healthy donors (308). Comparable results were observed by Pan et al in GD patients when compared against healthy donors (309). Notably, these Tregs may be nTregs and were characterized and measured solely on the basis of phenotype. Marazuela et al observed that AITD patients had a significantly higher frequency than healthy donors of CD4+GITR+ and CD4+FOXP3+ as well as CD4+IL-10+ in the peripheral blood, which they claim represents nTregs and iTregs, respectively. (310). Our data showed that patients with GD or HT had an adequate number of circulating Th10 cells, but whether these Th10 cells function as well as healthy donor Th10 cells in suppressing cytokine production or proliferation was not measured in our study. Two studies have demonstrated that CD4+CD25hi Tregs from AITD patients were less able to inhibit proliferation than their healthy donor counterparts (308,310).

The above studies were carried out in the peripheral blood, and the situation may not be the same in the thyroid tissue. A study by Nakano et al, who grouped GD and HT as AITD, showed a lower proportion of CD4+CD25+ Tregs among the intra-thyroidal lymphocytes in the thyroid than among blood lymphocytes (311).

Overall, our results show that thyroid self-antigens are able to induce IL-10 secretion in CD4+ T cells in healthy donors and in patients with GD or HT. Additionally, patients with GD or HT were not impaired or deficient in inducing an immuno-regulatory response as noted by the similar proportions of Th10 cells in healthy donors and both patient groups.

### IL-17 production by CD4+ T cells

HT has always been believed to be a Th1-mediated autoimmune disease (205,209), due to the increased production of IFN- $\gamma$ , IL-2 and TNF- $\alpha$  detected among HT patients (233–236). However, many autoimmune diseases such as RA, inflammatory bowel disease, multiple sclerosis and possibly even HT (37,38) may instead be driven by Th17 cells and their production of IL-17 rather than Th1 cells and IFN- $\gamma$ .

After incubation of intact PBMC with anti-CD3/anti-CD28 antibodies, in paper III, the proportion of Th17 cells did not differ between each patient group and healthy donors. However, incubation with the thyroid self-antigen TPO did induce higher proportions of Th17 cells in the naïve CD4+ T cell compartment of HT patients than of healthy donors or GD patients. This finding is novel, as Th17 induction by thyroid self-antigens has not been reported previously. This indicates that HT patients have a higher frequency of self-antigen specific Th17 cells than healthy donors, even though the frequency of dedicated Th17 cells, in general, is not elevated in patients.

In contrast to our results, Nanba et al and Figueiroa-Vega et al showed that a higher proportion of Th17 cells were detected in peripheral blood from HT patients than in healthy donors or GD patients after polyclonal stimulation with PMA/ionomycin (40,41). Shi et al also observed a higher baseline mRNA level of IL-17 among PBMC from HT patients than among PBMC from healthy donors (39).

It should be noted that the increase in the proportion of Th17 cells was not restricted to the self-antigen TPO. E. coli LPS, used as a foreign control antigen, was also able to increase the proportions of both naïve and memory Th17 cells in HT patients, compared to those of healthy controls or GD patients. This correlated well with McAleer et al who observed that E. coli LPS expanded pre-committed Th17 cells instead of de novo induction of Th17 differentiation (312,313).

Our data indicates that irrespective of the stimulus, TPO or E. coli LPS, CD4+ T cells from HT patients are more prone to differentiate into IL-17-producing cells than CD4+ T cells from healthy donors.

### Th17/Th10 ratio and Th17 differentiation

Th10 cells and Th17 cells have been investigated separately in AITD, but this study is the first to analyze their relative frequencies together. In paper III, we observed that Th0 cells among the healthy donors preferentially differentiated into Th10 cells, whereas for patients with GD or HT, Th0 cells preferentially differentiated into Th17 cells. The preferential differentiation of Th0 cells into Th17 cells in AITD patients could be a result of the surrounding microenvironment. Therefore, we quantified IL-1 $\beta$ , IL-6 and TGF- $\beta$ 1 in the culture supernatants knowing that the local cytokine environment is crucial to Th17 differentiation. However, which cytokines are the most important for Th17 differentiation is still under debate. To date, several cytokines have been implicated in Th17-cell differentiation, including IL-1 $\beta$ , IL-6, IL-21, IL-23, TNF- $\alpha$  and TGF- $\beta$  (37,42–46,314). We found that HT patients had a higher baseline concentration of IL-6 and TGF- $\beta$ 1 in unstimulated PBMC cultures than healthy donors. It should be noted that TGF- $\beta$ 1 was higher in HT patients than healthy donors, irrespective of whether TG, TPO or E. coli LPS was used as the stimulus. The higher baseline concentration of IL-6 and TGF- $\beta$ 1 may support the increased differentiation of Th17 cells in the HT patient group.

The role that TGF- $\beta$  may play in Th17 differentiation is intriguing. TGF- $\beta$  is a regulatory cytokine that aids in the differentiation of inducible Tregs (54,315). TGF- $\beta$  along with IL-6 may have a

more direct role in Th17 differentiation by inducing the expression of ROR $\gamma$ t and ROR $\alpha$  (49,316). However, TGF- $\beta$  may also have an indirect role with Th17 differentiation by limiting Th1 differentiation and thereby allowing the differentiation of Th17 cells (48). Moreover, the concentration of TGF- $\beta$  might also be crucial for Th17 differentiation, where low concentrations (1-10ng/mL) induces Th17 differentiation, and higher concentrations (50ng/mL) inhibits Th17 differentiation and promotes Treg differentiation (95,317).

The imbalance between pro-inflammatory and anti-inflammatory CD4+ T cell subsets, such as Th17, and Treg subsets, respectively, may be one of the pathogenic mechanisms in autoimmune disease (36). This gives credence to our hypothesis that the skewed Th17:Th10 ratio detected in AITD patients may play a role in AITD pathogenesis.

### **FOXP3 and Th17 plasticity**

There is a high degree of plasticity in the Th17/Treg differentiation pathways, but the biological relevance for this is still unclear. Studies have shown that FOXP3+ Tregs are able to produce IL-17 after PMA/ionomycin stimulation, or in an IL-1 $\beta$ -dependent way (101–104). It has also been demonstrated that these IL-17-producing FOXP3+ Tregs were expressing the Th17-specific transcription factor ROR $\gamma$ t constitutively alongside the expression of the Treg-specific transcription factor FOXP3 (102,104). If FOXP3+Tregs are able to produce IL-17 or even differentiate into Th17 cells that might help to explain why in some autoimmune diseases a higher percentage of Th17 cells are detected than in healthy individuals. It is still not clear whether these IL-17+FOXP3+ Tregs are able to maintain their suppressive function due to conflicting results (103,104).

In our study, both patient groups had a higher constitutive expression of FOXP3 $\Delta$ 2, but not of total FOXP3, than healthy donors in the unstimulated PBMC cultures. Thus, the patient groups expressed relatively more of the FOXP3 $\Delta$ 2 splice variant than healthy donors. CD4 was chosen as the housekeeping gene because the expression of CD4 does not alter after stimulation (318). Additionally, FOXP3 is expressed by CD4+ T cells and using a house-keeping gene that is specific to the cell population being studied is preferred. Full length FOXP3 functions as suppressors of ROR $\gamma$ t (RORC, human ortholog) and ROR $\alpha$ , as well as of the NFAT and NF- $\kappa$ B by binding to them and inhibiting their biological activity. Binding of FOXP3 to ROR $\gamma$ t and ROR $\alpha$  prevents Th17 differentiation, and allows the differentiation of Tregs (94,95,97). In contrast, FOXP3 $\Delta$ 2 is unable to suppress ROR $\gamma$ t and ROR $\alpha$ , as well as NF- $\kappa$ B because it is unable to bind (93–97,319). Mouse studies have shown that exon 2 is crucial for the binding of FOXP3 to ROR $\gamma$ t or ROR $\alpha$  or NF- $\kappa$ B (94,97) and is thought to be the vital part of the repressor domain (96). The inability of FOXP3 $\Delta$ 2 to bind to and inhibit ROR $\gamma$ t, ROR $\alpha$  and NF- $\kappa$ B relies upon the missing exon 2. ROR $\gamma$ t is the prevailing transcription factor for Th17 cells, and ROR $\alpha$  is upregulated in Th17 cells due to the presence of certain cytokines in the local cytokine environment (49,316). Therefore the inability of FOXP3 $\Delta$ 2 to bind and inhibit ROR $\gamma$ t and ROR $\alpha$  would allow the differentiation of Th17 cells, and could result in the skewed Th17: Th10 cell ratio observed in paper III.

In summary, our study shows that patients with GD or HT have a higher constitutive expression of FOXP3 $\Delta$ 2 than healthy donors. This elevated expression of FOXP3 $\Delta$ 2 in HT patients may help to explain the preferential differentiation of Th17 cells in HT patients in paper III.

### **Limitations of the study**

Considerations have to be made because all of my experiments in all three papers (I, II and III) were carried out on isolated lymphocytes from the peripheral blood. These may not be functionally or phenotypically similar to the intra-thyroidal lymphocytes driving the disease.

A limitation of our studies was the sparse number of samples per group. For many explorative studies, such as the ones we carried out, a sample size of 10-15 is the norm. In all our papers (I, II and III) we wanted to illustrate qualitative differences in the cytokine production between patients with GD or HT and healthy donors. A previous study by Glick et al, examining Tregs in AITD, had 7 GD patients and 13 HT patients, while Figueroa-Vega et al, studying Th17 cells in AITD, had 8 GD patients and 18 HT patients (41,308). The size of each sample group (paper II: 12 healthy donors, 12 GD patients; 12 HT patients; paper III: 15 healthy donors; 11 GD patients; 10 HT patients) and power calculation was based on previous studies in our group where significant differences were observed with 10-15 subjects in each group (320–322). However, with small sample groups and a low study power, there is a risk of making a type I or a type II error.

Another limitation was that the majority of the GD or HT patients that were recruited for papers II and III were treated with either methimazole or levothyroxine for varying periods of time before blood collection and participation in this PhD study. It should be taken into consideration that the cytokine production for the treated GD or HT patients might be altered due to anti-thyroid drugs, and therefore might be more similar to the cytokine production detected for healthy donors. This might have led us to underestimate the differences in cytokine production between patients and healthy donors. Several reports have linked an association between anti-thyroid medication and cytokine production; Weiss et al reported that anti-thyroid drugs inhibited the proper functioning of lymphocytes (323). Thionamides, a class of anti-thyroid drugs, have been shown to inhibit cytokine production due to the suppression of NF- $\kappa$ B (324). In contrast, Volpe et al reported that the thyroid status, itself, might have an effect on the immune system (325). Severe hyperthyroidism might affect the immune system by altering the numbers and activation status of CD4+ and CD8+ T cells, by increasing the serum concentrations of IL-2, as well as by altering the responsiveness of CD4+ T cells to the thyroid self-antigens (325).

However, it should be noted that all patients with GD or HT had antibody titres well above the normal range for either anti-TSHR or anti-TPO respectively at the time of blood sampling. This was an inclusion criterion for the studies in papers II and III. This indicates that all patients were immunologically active, even though some were receiving anti-thyroid medication or thyroid hormone.

### **Conclusions**

#### **Overall Conclusions of the study**

One of the main findings of this PhD study is that the human thyroid self-antigen TG is able to induce antigen-specific production of IL-10 in both CD19+ B cells and CD4+ T cells, in healthy donors as well as in patients with GD or HT. Moreover, TPO, another thyroid specific self-antigen, induced higher frequencies of Th17 cells within the naïve CD4+ T-cell compartment in HT patients than healthy donors. This increased frequency or skewing towards Th17 cells in HT patients could be due to an elevated baseline production of IL-6 and TGF- $\beta$ 1 by PBMC or to an increased expression of mRNA encoding FOXP3 $\Delta$ 2. Notably, the proportions of Th10 cells of GD or HT patients were similar to those in healthy controls.

Furthermore, we demonstrated that patients with GD or HT were not impaired or deficient with regards to inducing an immuno-regulatory response in terms of IL-10 production by CD19+ B cells. IL-10 production by B10 cells was similar between healthy donors and patients with GD or HT, irrespective of the stimulus used. We also showed that B10 cells among healthy donors and patients with GD or HT did not separate into one clearly defined phenotypic subgroup, nor did they express the surface markers that have previously been associated with B10 cells. We did, however, find that B10 cells from HT patients and GD patients had a frequency of B10 cells expressing CD25 and TIM-1.

Thus, these studies have provided insights and extended our understanding of the pathogenesis of GD and HT in terms of the immune system's reaction to thyroid self-antigens.

### Perspectives

There are still so many unanswered questions that remain to be answered with regards to the pathogenesis of AITD. It is still not clear as to why thyroid autoimmunity starts to begin with and by what mechanisms autoimmunity is allowed to progress. Some future experiments to aid in our understanding of the pathogenesis of AITD could be:

- To measure the frequency of Th10 and Th17 cells as well as their cytokine products IL-10 and IL-17 in the thyroid tissue of AITD patients.
- To measure the functionality of the IL-10-producing CD4+ T cells or IL-10-producing B cells, in terms of inhibiting cytokine production, proliferation or differentiation of effector CD4+ T cells from AITD patients in the peripheral blood and thyroid tissue.
- To characterize the phenotype of B10 cells in the thyroid tissue of AITD patients.
- To measure other anti-inflammatory cytokines such as TGF- $\beta$  and/or IL-35. IL-35 has recently been shown to have a regulatory role in autoimmunity (326,327).

From our data HT patients had a higher frequency of Th17 cells and IL-17 production. Inhibiting the Th17/IL-17 axis might be a useful therapeutic treatment. Currently, there are three anti-IL-17A drugs, namely secukinumab, ixekizumab and brodalumab, undergoing clinical trials (328). Secukinumab is a fully human anti-IL-17A monoclonal antibody (mAb) with IgG1 subtype, ixekizumab is a humanized anti-IL-17A mAb, whereas brodalumab is a fully human anti-IL-17RA mAb, which is directed against the IL-17A receptor (328). These therapeutic agents allow the inhibition of IL-17 production as well as the blocking of IL-17A receptor. These therapeutic agents have shown great promise in reducing IL-17 production in various autoimmune diseases such as RA, psoriasis and Crohn's disease (328,329). These therapeutic agents might also have a positive effect in patients with HT by blocking the production of IL-17 or its receptor. Intriguingly, there is also evidence that therapeutic agents can be produced to inhibit the transcription factors ROR- $\gamma$ t and ROR- $\alpha$ , which are central to Th17 differentiation. If these transcription factors can be blocked that would inhibit Th17 differentiation and reduce IL-17 production (330).

### Summary

Autoimmune diseases occur due to faulty self-tolerance. Graves' disease (GD) and Hashimoto's thyroiditis (HT) are classic examples of organ-specific autoimmune diseases. GD is an antibody-mediated disease where autoantibodies are produced against the thyroid stimulating hormone receptor (TSHR). HT is

primarily a T-cell mediated disease, and whether B cells play a pathogenic role in the pathogenesis is still unclear. Both GD and HT are characterized by infiltration of the thyroid gland by self-reactive T cells and B cells.

In the first paper of this thesis, the role of regulatory B cells (Bregs) and regulatory T cells (Tregs) were investigated in the context of GD and HT. First, we studied the role of the thyroid self-antigen, thyroglobulin (TG) in healthy donors. The self-antigen TG, but not the foreign recall antigen tetanus toxoid (TT), was able to induce interleukin 10 (IL-10) secretion by B cells and CD4+ T cells. These IL-10 producing B cells (B10 cells) from healthy donors were enriched with the CD5+ and CD24hi phenotype. In addition, TG was able to induce IL-6 production by B cells. In contrast, TT induced production of Th1-type pro-inflammatory cytokines including interferon-gamma (IFN- $\gamma$ ) and IL-2.

In the second paper, the frequency and phenotype of B10 was investigated in healthy donors and patients with GD or HT. The frequencies of B10 cells were similar in the three groups, irrespective of whether IL-10 was induced by a combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin, by CpG oligodeoxynucleotides (ODN) 2006, or by TG. Several phenotypes have been associated with B10 cells such as CD5+, CD25+, TIM-1+, CD24hiCD38hi and CD27+CD43+. We found that larger proportions of B10 cells in patients with GD or HT were CD25+ and TIM-1+ than B10 cells in healthy donors. In healthy donors, B10 cells were CD24hiCD38-, whereas for HT patients these cells were primarily CD24intCD38int. For GD patients, we found lower proportions of B10 cells within the CD27+CD43- and CD27-CD43- fractions than for healthy donors. Our data show that GD and HT are not associated with decreased frequencies of B10 cells. Accordingly, B10 cells may not be confined to one phenotype or subset of B cells.

In the third paper, we studied the balance between IL-17-producing CD4+ T cells (Th17 cells) and IL-10-producing CD4+ T cells (Th10 cells) in healthy donors and patients with GD or HT. In HT patients, we found increased proportions of naïve Th17 cells after stimulation with the thyroid self-antigen thyroid peroxidase (TPO) and the Escherichia coli lipopolysaccharide (E. coli LPS). The proportions of Th10 cells were similar in healthy donors and in HT patients after antigen-specific stimulation. After TG stimulation, an increased Th17:Th10 ratio was found in HT patients within the naïve T cell compartment. Taken together, these data indicate that the thyroid self-antigens TG and TPO induced a skewed Th17:Th10 differentiation in HT patients. IL-6 and TGF- $\beta$  have been reported to be important for human Th17 differentiation and, accordingly, HT patients showed higher baseline production of IL-6 and TGF- $\beta$ 1 than healthy donors. Moreover, the baseline expression of mRNA encoding the transcription factor Forkhead box protein 3 (FOXP3) was similar in HT patients and healthy donors, but HT patients displayed higher constitutive expression of the splice variant FOXP3 $\Delta$ 2, lacking exon 2, than healthy donors. Full-length FOXP3 has been shown to inhibit Th17 differentiation, while FOXP3 $\Delta$ 2 does not. Thus, increased IL-6 and TGF- $\beta$ 1 in the microenvironment and the increased expression of FOXP3 $\Delta$ 2 may contribute to the skewing of Th17 cells in HT patients.

In conclusion, the human thyroid self-antigen TG is able to induce antigen-specific production of IL-10 in CD19+ B cells and CD4+ T cells among healthy donors and patients with GD or HT. Our data indicates that patients with GD or HT were not impaired in producing IL-10 and thus an immuno-regulatory response. Additionally, TPO, a thyroid self-antigen, induced a higher frequency of Th17 cells in HT. This indicates that Th17 cells may play an important role in HT pathogenesis.

## List of Abbreviations

Ab	Antibody
ADCC	Antibody dependent cell mediated cytotoxicity
AITD	Autoimmune thyroid disease
APC	Antigen presenting cell
B10	IL-10-producing B cells
BCR	B cell receptor
Breg	Regulatory B cells
CD	Cluster of Differentiation
CTLA4	Cytotoxic T-lymphocyte associated protein 4
CTL	Cytotoxic T lymphocytes
EAE	Experimental autoimmune encephalomyelitis
EAT	Experimental autoimmune thyroiditis
E. coli LPS	Escherichia coli Lipopolysaccharide
FOXP3	Forkhead box protein 3
GC	Germinal center
GD	Graves' disease
GITR	Glucocorticoid-induced TNFR family related gene
HLA	Human leukocyte antigen
HT	Hashimoto thyroiditis
IFN- $\gamma$	Interferon-gamma
IL	Interleukins
iTregs	Inducible regulatory T cells
MHC	Major Histocompatibility complex
NFAT	Nuclear factor of activated T cells
NF- $\kappa$ B	Nuclear factor kappa-light-chain-enhancer of activated B cells
nTregs	Natural regulatory T cells
PBMC	Peripheral blood mononuclear cells
RA	Rheumatoid arthritis
ROR- $\alpha$	retinoic acid receptor-related orphan receptor – alpha
RORC	retinoic acid receptor-related orphan receptor C
ROR $\gamma$ t	retinoic acid receptor-related orphan receptor –gamma t
SLE	Systemic lupus erythematosus
STAT1	signal transducer and transcription activator 1
STAT4	signal transducer and transcription activator 4
TBAb	Thyroid blocking antibody
TCR	T cell receptor
TG	Thyroglobulin
TGF- $\beta$	Transforming growth factor-beta
Th	T helper cell
Th0	Naive CD4+ T cells
TNF- $\alpha$	Tumor necrosis factor - alpha
TPO	Thyroid peroxidase
TRAb	Thyroid stimulating hormone receptor antibody
Treg	Regulatory T cells
TSH	Thyroid stimulating hormone
TSAb	Thyroid stimulating antibody
TSHR	Thyroid stimulating hormone receptor
TT	Tetanus toxoid

## References

1. Sinha A, Lopez M, McDevitt H. Autoimmune diseases: the failure of self tolerance. *Science*. 1990 Jun 15;248:1380–8.
2. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. *Nat Rev Immunol*. 2002 Mar;2:195–204.
3. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. *Nature*. 2005 Jun 2;435:590–7.

4. Palmer E. Negative selection--clearing out the bad apples from the T-cell repertoire. *Nat Rev Immunol*. 2003 May;3:383–91.

5. Smilek DE, Ehlers MR, Nepom GT. Restoring the balance: immunotherapeutic combinations for autoimmune disease. *Dis Model Mech*. 2014 May;7(5):503–13.

6. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. *Annu Rev Immunol*. 2003 Jan;21:139–76.

7. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. *Nat Rev Immunol*. 2005 Oct;5:772–82.

8. Tobón GJ, Izquierdo JH, Cañas CA. B lymphocytes: development, tolerance and their role in autoimmunity-focus on systemic lupus erythematosus. *Autoimmune Dis*. 2013 Jan;2013:827254.

9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor  $\alpha$ -chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol*. 1995 Apr 1;155:1151–64.

10. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings M. Type 1 T regulatory cells. *Immunol Rev*. 2001;182:68–79.

11. Mizoguchi A, Bhan A. A Case for Regulatory B Cells. *J Immunol*. 2006 Jan 3;176:705–10.

12. Mauri C, Ehrenstein MR. The “short” history of regulatory B cells. *Trends Immunol*. 2008 Jan;29:34–40.

13. Bluestone JA. Mechanisms of tolerance. *Immunol Rev*. 2011 May;241:5–19.

14. Júnior DM, Araújo JAP, Catelan TTT, de Souza AWS, Cruvinel W de M, Andrade LEC, et al. Immune System – Part II Basis of the immunological response mediated by T and B lymphocytes. *Bras J Rheumatol*. 2010;50:552–80.

15. Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. *Nature*. 1996;383:787–93.

16. Crome S, Wang A, Levings M. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. *Clin Exp Immunol*. 2009 Feb;159:109–19.

17. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol*. 1986 Jul 1;136:2348–57.

18. Mosmann TR, Coffman R. TH1 AND TH2 CELLS : Different Patterns of Lymphokine Functional Properties. *Annu Rev Immunol*. 1989;7:145–73.

19. Del Prete G, Romagnani S. The role of TH1 and TH2 subsets in human infectious diseases. *Trends Microbiol.* 1994 Jan;2:4–6.
20. Romagnani S. The Th1/Th2 paradigm. *Immunol Today.* 1997 Jun;18:263–6.
21. Szabo S, Kim S, Costa G, Zhang X, Fathman C, Glimcher L. A novel transcription factor, T-bet, directs Th1 lineage commitment. *Cell.* 2000 Mar 17;100:655–69.
22. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. *Blood.* 2008 Sep 1;112:1557–69.
23. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. *Arthritis Res Ther.* 2009 Jan;11:257.
24. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. *Nature.* 1996;380:627–30.
25. Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 Is Necessary and Sufficient for IL-4's Role in Th2 Differentiation and Cell Expansion. *J Immunol.* 2001 Jun 15;166:7276–81.
26. Le Gros G, Ben-Sasson S, Seder R, Finkelman F, Paul W. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. *J Exp Med.* 1990;172:921–9.
27. Swain SL, Weinberg A, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. *J Immunol.* 1990 Dec 1;145:3796–806.
28. Fishman M, Perelson A. Th1/Th2 Cross Regulation. *J Theor Biol.* 1994;170:25–6.
29. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. *Science.* 2005 Jan 21;307:430–3.
30. Usui T, Nishikomori R, Kitani A, Strober W. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. *Immunity.* 2003 Mar;18:415–28.
31. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream JH, O'Shea JJ, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. *J Exp Med.* 2006 Mar 20;203:755–66.
32. Romagnani S. Regulation of the development of type 2 T-helper cells in allergy. *Curr Opin Immunol.* 1994 Dec;6:838–46.
33. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. *J Biol Chem.* 2003 Jan 17;278:1910–4.
34. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol.* 2005 Nov;6:1123–32.
35. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Defining the human T helper 17 cell phenotype. *Trends Immunol.* Elsevier Ltd; 2012 Oct;33:505–12.
36. Afzali B, Lombardi G, Lechler R, Lord G. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. *Clin Exp Immunol.* 2007 Apr;148:32–46.
37. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. *Immunol Rev.* 2008;223:87–113.
38. Kurts C. Th17 cells: a third subset of CD4+ T effector cells involved in organ-specific autoimmunity. *Nephrol Dial Transplant.* 2008 Mar;23:816–9.
39. Shi Y, Wang H, Su Z, Chen J, Xue Y, Wang S, et al. Differentiation Imbalance of Th1/ Th17 in Peripheral Blood Mononuclear Cells Might Contribute to Pathogenesis of Hashimoto's Thyroiditis. *Scand J Immunol.* 2010;72:250–5.
40. Nanba T, Watanabe M, Inoue N, Iwatani Y. Increases of the Th1-Th2 Cell Ratio in Severe Hashimoto's Disease and in the Proportion of Th17 Cells in Intractable Graves' Disease. *Thyroid.* 2009;19:495–501.
41. Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, Sánchez-Madrid F, González-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. *J Clin Endocrinol Metab.* 2010 Feb;95:953–62.
42. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. *Nature.* 2008 Jul 17;454:350–2.
43. Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol.* 2007 Sep;8:942–9.
44. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgamma. *Nat Immunol.* 2008 Jun;9:641–9.
45. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol.* 2007 Sep;8:950–7.
46. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. *Nat Immunol.* 2008 Jul;9:650–7.
47. O'Garra A, Stockinger B, Veldhoen M. Differentiation of human TH -17 cells does require TGF-β ! *Nat Immunol.* 2008;9:588–90.



48. Santarlaschi V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. *Eur J Immunol.* 2009 Jan;39:207–15.
49. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell.* 2006 Sep 22;126:1121–33.
50. Unutmaz D. RORC2: the master of human Th17 cell programming. *Eur J Immunol.* 2009 Jun;39:1452–5.
51. Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol.* 2005;6:1133–41.
52. Acosta-Rodriguez E V, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. *Nat Immunol.* 2007;8:639–46.
53. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. *Nat Rev Immunol.* 2003 Mar;3:253–7.
54. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)/CD4(+)/CD25(+) regulatory T cells are not mirror images of each other. *Trends Immunol.* 2008 Sep;29:429–35.
55. Khattri R, Cox T, Yasayko S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat Immunol.* 2003 Apr;4:337–42.
56. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol.* 2003 Apr;4:330–6.
57. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science.* 2003 Feb 14;299:1057–61.
58. Ramsdell F, Celltech R. Foxp3 and Natural Regulatory T Cells : Key to a Cell Lineage ? *Immunity.* 2003;19:165–8.
59. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol.* 2009 Oct;21:1105–11.
60. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med.* 1995;182:459–65.
61. Saito T. Negative regulation of T cell activation. *Curr Opin Immunol.* 1998;10:313–21.
62. Lanier LL, Fallon SO, Somoza C, Phillips JH, Linsley PS, Okumura K, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL. *J Immunol.* 1995;154:97–105.
63. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat Immunol.* 2005 Nov;6:1142–51.
64. Thornton A, Donovan E, Piccirillo C, Shevach E. Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function. *J Immunol.* 2004 May 20;172:6519–23.
65. Thornton AM, Shevach EM. CD4+CD25+ Immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. *J Exp Med.* 1998;188:287–96.
66. Cottrez F, Groux H. Specialization in tolerance: innate CD4+CD25+ versus acquired Tr1 and TH3 regulatory T cells. *Transplantation.* 2004 Jan 15;77:S12–S15.
67. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits responses and prevents colitis. *Nature.* 1997;389:737–42.
68. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. *Immunol Rev.* 2006 Aug;212:28–50.
69. Foussat A, Cottrez F, Brun V, Fournier N, Breitmayer J, Groux H. A Comparative Study between T Regulatory Type 1 and CD4+CD25+ T Cells in the Control of Inflammation. *J Immunol.* 2003 Nov 7;171:5018–26.
70. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annu Rev Immunol.* 2012 Jan;30:733–58.
71. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. *Blood.* 2005 Feb 1;105:1162–9.
72. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. *J Autoimmun.* 2003 Jun;20:281–5.
73. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. *Nature.* 2003;421:388–92.
74. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. *Cytokine Growth Factor Rev.* 2010 Oct;21:331–44.
75. Moore K, de Waal Malefyt R, Robert L, O'Garra A. Interleukin-10 and the Interleukin-10 Receptor. *Annu Rev Immunol.* 2001;19:683–765.
76. Howard M, O'Garra A, Ishida H, De Waal Malefyt R, De Vries J. Biological properties of interleukin 10. *J Clin Immunol.* 1992 Mar;12:239–47.
77. Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. Transforming growth factor-beta regulation of immune responses. *Annu Rev Immunol.* 2006 Jan;24:99–146.

78. Oh SA, Li MO. TGF- $\beta$ : guardian of T cell function. *J Immunol.* 2013 Oct 15;191:3973–9.
79. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? *Immunity.* Elsevier Inc.; 2009 May;30:626–35.
80. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. *J Exp Med.* 2001 Jun 4;193:1303–10.
81. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. *Proc Natl Acad Sci U S A.* 2003 Sep 16;100:10878–83.
82. Collison LW, Pillai MR, Chaturvedi V, Vignali DAA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. *J Immunol.* 2009 May 15;182:6121–8.
83. Walker MR, Kaspirowicz DJ, Gersuk VH, Bènard A, Landeghen M Van, Buckner JH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4 + CD25- T cells. *J Clin Invest.* 2003;112:1437–43.
84. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. *Proc Natl Acad Sci USA.* 2005;102:4103–8.
85. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and Induced CD4+CD25+ Cells Educate CD4+CD25- Cells to Develop Suppressive Activity: The Role of IL-2, TGF-beta , and IL-10. *J Immunol.* 2004 Apr 20;172:5213–21.
86. Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. *Eur J Immunol.* 2007 Jan;37:129–38.
87. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. *J Allergy Clin Immunol.* 2007 Oct;120:744–50.
88. Kobayashi I, Shiari R, Yamada M, Kawamura N, Okano M, Yara A, et al. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). *J Med Genet.* 2001 Dec;38:874–6.
89. Ryder LR, Bartels EM, Woetmann A, Madsen HO, Odum N, Bliddal H, et al. FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. *APMIS.* 2012 May;120:387–96.
90. Smith E, Finney H, Nesbitt A, Ramsdell F, Robinson M. Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. *Immunology.* 2006;119:203–11.
91. Allan S, Passerini L, Bacchetta R, Crellin N, Dai M, Orban P, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. *J Clin Invest.* 2005;115:3276–84.
92. Schubert L, Jeffery E, Zhang Y, Ramsdell F, Ziegler S. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. *J Biol Chem.* 2001 Oct 5;276:37672–9.
93. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. *Proc Natl Acad Sci U S A.* 2005 Apr 5;102:5138–43.
94. Du J, Huang C, Zhou B, Ziegler S. Isoform-Specific Inhibition of ROR-alpha Mediated Transcriptional Activation by Human FOXP3. *J Immunol.* 2008 Mar 19;180:4785–92.
95. Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victoria GD, et al. TGF- $\beta$ -induced Foxp3 inhibits Th17 cell differentiation by antagonizing ROR $\gamma$ t function. *Nature.* 2008;453:236–40.
96. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen A-M, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. *Leukemia.* 2008 Dec;22:2230–9.
97. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. *Clin Exp Immunol.* 2009 Feb;159:120–30.
98. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. *J Exp Med.* 2007;204:1849–61.
99. Maggi L, Santarlasci V, Capone M, Rossi MC, Querci V, Mazzoni A, et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. *Eur J Immunol.* 2012 Dec;42:3180–8.
100. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, et al. Pathogen-induced human TH17 cells produce IFN- $\gamma$  or IL-10 and are regulated by IL-1 $\beta$ . *Nature.* Nature Publishing Group; 2012 Apr 26;484:514–8.
101. Koenen HJPM, Smeets RL, Vink PM, van Rijssen E, Boots AMH, Joosten I. Human CD25<sup>high</sup>Foxp3<sup>pos</sup> regulatory T cells differentiate into IL-17-producing cells. *Blood.* 2008 Sep 15;112:2340–52.
102. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor ROR $\gamma$ mat. *Proc Natl Acad Sci U S A.* 2009 May 26;106:8635–40.
103. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. *Blood.* 2009 Apr 30;113:4240–9.

104. Voo KS, Wang Y-H, Santori FR, Boggiano C, Wang Y-H, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. *Proc Natl Acad Sci U S A*. 2009 Mar 24;106:4793–8.
105. Hardy R, Hayakawa K. B cell development pathways. *Annu Rev Immunol*. 2001;19:595–621.
106. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. *Blood*. 2008 Sep 1;112:1570–80.
107. Lanzavecchia A. Antigen-Specific Interaction between T and B Cells. *Nature*. 1985;314:537–9.
108. Bishop G, Hostager B. B lymphocyte activation by contact-mediated interactions with T lymphocytes. *Curr Opin Immunol*. 2001 Jun;13:278–85.
109. Yanaba K, Bouaziz J-D, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. *Immunol Rev*. 2008 Jun;223:284–99.
110. Kantor AB. The development and repertoire of B-1 cells (CD5 B cells). *Immunol Today*. 1991;12:389–91.
111. Allman D, Pillai S. Peripheral B cell subsets. *Curr Opin Immunol*. 2008;20:149–57.
112. Boes M, Prodeus A, Schmidt T, Carroll M, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. *J Exp Med*. 1998 Dec 21;188:2381–6.
113. Baumgarth N, Herman O, Jager G, Brown L, Herzenberg L, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. *J Exp Med*. 2000 Jul 17;192:271–80.
114. Hardy RR. B-1 B Cell Development. *J Immunol*. 2006 Aug 18;176:2749–54.
115. Zhong X, Gao W, Degauque N, Bai C, Lu Y, Kenny J, et al. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. *Eur J Immunol*. 2007 Sep;37:2400–4.
116. Lydyard PM, Lamour A, MacKenzie LE, Jamin C, Mageed RA, Youinou P. CD5+ B cells and the immune system. *Immunol Lett*. 1993 Oct;38:159–66.
117. Zhou Z, Tzioufas AG, Notkins AL. Properties and function of polyreactive antibodies and polyreactive antigen-binding cells. *J Autoimmun*. 2007;29:219–28.
118. Hardy R, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. *Science (80- )*. 1987;236:81–3.
119. Suzuki N, Sakane T, Engleman E. Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. *J Clin Invest*. 1990 Jan;85:238–47.
120. Casali P, Burastero S, Nakamura M, Inghirami G, Notkins A. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. *Science*. 1987 Apr 3;236:77–81.
121. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. *Blood*. 2002;100:4537–43.
122. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. *Immunol Rev*. 2004 Feb;197:179–91.
123. Ekerfelt C, Ernerudh J, Solderst G, Vrethem M. CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy. *Clin Exp Immunol*. 1995;101:346–50.
124. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. *J Exp Med*. 2011 Jan 17;208:67–80.
125. Carsetti R, Kohler G, Lamers MC. Transitional B Cells Are the Target of Negative Selection in the B Cell Compartment. *J Exp Med*. 1995;181:2129–40.
126. Agrawal S, Smith S, Tangye S, Sewell W. Transitional B cell subsets in human bone marrow. *Clin Exp Immunol*. 2013 Oct;174:53–9.
127. Allman D, Lindsley R, DeMuth W, Rudd K, Shinton S, Hardy R. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. *J Immunol*. 2001 Dec 15;167:6834–40.
128. Chung JB, Sater RA, Fields ML, Erikson J, Monroe JG. CD23 defines two distinct subsets of immature B cells which differ in their responses to T cell help signals. *Int Immunol*. 2002 Feb;14:157–66.
129. Petro JB, Gerstein RM, Lowe J, Carter RS, Shinnars N, Khan WN. Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling. *J Biol Chem*. 2002 Dec 13;277:48009–19.
130. Loder F, Mutschler B, Ray R, Paige C, Sideras P, Torres R, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. *J Exp Med*. 1999 Jul 5;190:75–89.
131. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. *Blood*. 2005 Jun 1;105:4390–8.
132. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. *Clin Immunol*. 2008 Apr;127:14–25.

133. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Looney RJ, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. *J Immunol*. 2009;182:5982–93.
134. Suryani S, Fulcher D a, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. *Blood*. 2010 Jan 21;115:519–29.
135. Martin F, Kearney J. B1 cells: similarities and differences with other B cell subsets. *Curr Opin Immunol*. 2001 Apr;13:195–201.
136. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. *Nat Rev Immunol*. 2009 Nov;9:767–77.
137. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innatelike antibody-producing lymphocytes. *Nat Rev Immunol*. 2013;13:118–32.
138. Oliver AM, Martin F, Kearney JF. IgMhigh CD21high Lymphocytes Enriched in the Splenic Marginal Zone Generate Effector Cells More Rapidly Than the Bulk of Follicular B Cells. *J Immunol*. 1999;162:7198–207.
139. Cariappa A, Mazo IB, Chase C, Shi HN, Liu H, Li Q, et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. *Immunity*. 2005 Oct;23:397–407.
140. Attanavanich K, Kearney J. Marginal Zone, but Not Follicular B Cells, Are Potent Activators of Naive CD4 T Cells. *J Immunol*. 2004 Jan 5;172:803–11.
141. Kraal G. Antigens take the shuttle. *Nat Immunol*. 2008 Jan;9:11–2.
142. Cinamon G, Zachariah MA, Lam OM, Foss Jr FW, Cyster JG. Follicular shuttling of marginal zone B cells facilitates antigen transport. *Nat Immunol*. 2008;9:54–62.
143. Spencer J, Perry ME, Dunn-Walters DK. Human marginal-zone B cells. *Immunol Today*. 1998 Sep;19:421–6.
144. Wolf S, Dittel B, Hardardottir F, Janeway C. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. *J Exp Med*. 1996 Dec 1;184:2271–8.
145. Fillatreau S, Sweeney CH, McGeachy MJ, Gray D, Anderson SM. B cells regulate autoimmunity by provision of IL-10. *Nat Immunol*. 2002 Oct;3:944–50.
146. Mizoguchi E, Mizoguchi A, Preffer F, Bhan A. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. *Int Immunol*. 2000 May;12:597–605.
147. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic Intestinal Inflammatory Condition Generates IL-10-Producing Regulatory B Cell Subset Characterized by CD1d Upregulation. *Immunity*. 2002;16:219–30.
148. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of Arthritis by Interleukin 10-producing B Cells. *J Exp Med*. 2003;197:489–501.
149. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. *Arthritis Res Ther. BioMed Central Ltd*; 2012 Jan;14:R32.
150. O'Garra A, Howard M. IL-10 Production by CD5 B Cells. *Ann N Y Acad Sci*. 1992 May 17;651:182–99.
151. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. *Immunity*. 2010 Jan 29;32:129–40.
152. Griffin DO, Rothstein TL. A small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupus. *J Exp Med*. 2011 Dec 19;208:2591–8.
153. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. *J Clin Invest*. 2011;121:3645–56.
154. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. *Blood*. 2011 Jan 13;117:530–41.
155. Cantaert T, Doorenspleet ME, Francosalinas G, Paramarta JE, Klarenbeek PL, Tiersma Y, et al. Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis. *Arthritis Rheum*. 2012 Jun;64:1859–68.
156. Zha B, Wang L, Liu X, Liu J, Chen Z, Xu J, et al. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves' disease. *PLoS One*. 2012 Jan;7:e49835.
157. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. *Autoimmun Rev*. 2012;11:670–7.
158. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. *Sci Transl Med*. 2013 Feb 20;5:173ra23.
159. Van der Vlugt L, Mlejnek E, Ozir-Fazalalikhani A, Janssen Bonas M, Dijkman T, Labuda L, et al. CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide. *Clin Exp Allergy*. 2013 Apr;44:517–28.
160. Daien CI, Gailhac S, Mura T, Audo R, Combe B, Hahne M, et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. *Arthritis Rheum*. 2014;66:2037–46.

161. Liu J, Zhan W, Kim CJ, Clayton K, Zhao H, Lee E, et al. IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. *PLoS One*. 2014 Jan;9:e89236.
162. Bouaziz J-D, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A, et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. *Eur J Immunol*. 2010 Oct;40:2686–91.
163. Rapoport B, Chazenbalk G, Jaume J, McLachlan S. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. *Endocr Rev*. 1998 Dec;19:673–716.
164. Weetman A. Graves' disease. *N Engl J Med*. 2000;343:1236–48.
165. Chistiakov DA. Immunogenetics of Hashimoto's thyroiditis. *J Autoimmune Dis*. 2005 Mar 11;2:1.
166. Dayan C, Daniels G. Chronic Autoimmune Thyroiditis. *N Engl J Med*. 1996;335:99–107.
167. Weetman AP. Determinants of autoimmune thyroid disease. *Nat Immunol*. 2001 Sep;2:769–70.
168. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves' disease. *Autoimmun Rev*. 2014;13:398–402.
169. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. *Eur J Endocrinol*. 2001 Oct 1;145:391–6.
170. Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. *Autoimmun Rev Elsevier B.V.*; 2014;13:391–7.
171. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. *J Autoimmun*. 2009;32:231–9.
172. Vanderpump MP. The epidemiology of thyroid disease. *Br Med Bull*. 2011 Jan;99:39–51.
173. Brix TH, Hegedüs L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. *Clin Endocrinol (Oxf)*. 2012 Apr;76:457–64.
174. Brix TH, Kyvik KO, Hegedu L. A Population-Based Study of Chronic Autoimmune Hypothyroidism in Danish Twins. *J Clin Endocrinol Metab*. 2000;85:536–9.
175. Knudsen N, Jørgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. *Clin Endocrinol (Oxf)*. 1999;51:361–7.
176. Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. *Eur J Endocrinol*. 2014 Jun;170:R241–R252.
177. Brix TH, Knudsen GPS, Kristiansen M, Kyvik KO, Orstavik KH, Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. *J Clin Endocrinol Metab*. 2005 Nov;90:5949–53.
178. Brix TH, Christensen K, Holm N V, Harvald B, Hegedüs L. A population-based study of Graves' disease in Danish twins. *Clin Endocrinol (Oxf)*. 1998;48:397–400.
179. Brix TH, Kyvik KO, Christensen K, Twin TD. Evidence for a Major Role of Heredity in Graves' Disease : A Population-Based Study of Two Danish Twin Cohorts. *J Clin Endocrinol Metab*. 2001;86:930–4.
180. Weetman AP. Autoimmune thyroid disease: propagation and progression. *Eur J Endocrinol*. 2003;148:1–9.
181. Tomer Y, Hasham A, Davies TF, Stefan M, Concepcion E, Keddache M, et al. Fine mapping of loci linked to autoimmune thyroid disease identifies novel susceptibility genes. *J Clin Endocrinol Metab*. 2013 Jan;98:E144–E152.
182. Bülow Pedersen I, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. *J Clin Endocrinol Metab*. 2002 Oct;87:4462–9.
183. Vejbjerg P, Knudsen N, Perrild H, Laurberg P, Carlé A, Pedersen IB, et al. Lower prevalence of mild hyperthyroidism related to a higher iodine intake in the population: prospective study of a mandatory iodization programme. *Clin Endocrinol (Oxf)*. 2009 Sep;71:440–5.
184. Andersen S, Iversen F, Terpling S, Pedersen KM, Gustenhoff P, Laurberg P. More hypothyroidism and less hyperthyroidism with sufficient iodine nutrition compared to mild iodine deficiency--a comparative population-based study of older people. *Maturitas*. 2009 Oct 20;64:126–31.
185. Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. *J Clin Endocrinol Metab*. 2007 Aug;92:3122–7.
186. Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette Smoking and Risk of Clinically Overt Thyroid Disease. *Arch Intern Med*. 2000;160:661–6.
187. Andersen SL, Olsen J, Wu C Sen, Laurberg P. Smoking reduces the risk of hypothyroidism and increases the risk of hyperthyroidism: evidence from 450,842 mothers giving birth in Denmark. *Clin Endocrinol (Oxf)*. 2014 Feb;80:307–14.
188. Hegedüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. *J Endocrinol Invest*. 2004;27:265–71.

189. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Moderate alcohol consumption may protect against overt autoimmune hypothyroidism: a population-based case-control study. *Eur J Endocrinol*. 2012 Oct;167:483–90.
190. Carlé A, Bülow Pedersen I, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Graves' hyperthyroidism and moderate alcohol consumption: evidence for disease prevention. *Clin Endocrinol (Oxf)*. 2013 Jul;79:111–9.
191. Segundo C, Rodríguez C, Aguilar M, García-Poley A, Gavián I, Bellas C, et al. Differences in thyroid-infiltrating B lymphocytes in patients with Graves' disease: relationship to autoantibody detection. *Thyroid*. 2004 May;14:337–44.
192. Wang SH, Baker JR. The role of apoptosis in thyroid autoimmunity. *Thyroid*. 2007 Oct;17:975–9.
193. Ben-Skowronek I, Sierocinska-Sawa J, Szewczyk L, Korobowicz E. Interaction of lymphocytes and thyrocytes in Graves' disease and nonautoimmune thyroid diseases in immunohistochemical and ultrastructural investigations. *Horm Res*. 2009 Jan;71:350–8.
194. Armengol MP, Juan M, Lucas-Martin A, Jaraquemada D, Gallart T, Pujol-Borrell R. Thyroid Autoimmune Disease: Demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. *Am J Pathol*. 2001;159:861–73.
195. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. *Nat Rev Immunol*. 2009 Dec;9:845–57.
196. Rapoport B, McLachlan SM. Thyroid autoimmunity. *J Clin Invest*. 2001;108:1253–9.
197. Latrofa F, Chazenbalk GD, Pichurin P, Chen C-R, McLachlan SM, Rapoport B. Affinity-enrichment of thyrotropin receptor autoantibodies from Graves' patients and normal individuals provides insight into their properties and possible origin from natural antibodies. *J Clin Endocrinol Metab*. 2004 Sep;89:4734–45.
198. Ajjan R, Weetman A. Techniques to quantify TSH receptor antibodies. *Nat Clin Pract Endocrinol Metab*. 2008 Aug;4:461–8.
199. Rees Smith B, Sanders J, Evans M, Tagami T, Furmaniak J. TSH Receptor – Autoantibody Interactions. *Horm Metab Res*. 2009 May 20;41:448–55.
200. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. *Immunol Res*. 2012 Dec;54:191–203.
201. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves' disease. *Thyroid*. 2007 Oct;17:911–22.
202. Mizutori Y, Chen C-R, Latrofa F, McLachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. *J Clin Endocrinol Metab*. 2009 Mar;94:927–35.
203. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. *J Clin Invest*. 2003;111:1897–904.
204. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrell R, Jaraquemada D. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. *Eur J Immunol*. 1997;27:3290–302.
205. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA. Different Cytokine mRNA Profiles in Graves' Disease, Hashimoto's Thyroiditis, and Nonautoimmune Thyroid Disorders Determined by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). *Thyroid*. 1996 Apr;6:97–106.
206. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan S, Rapoport B. Prevention of Autoantibody-Mediated Graves'-Like Hyperthyroidism in Mice with IL-4, a Th2 Cytokine. *J Immunol*. 2003 Apr 1;170:3522–7.
207. Fiorentino D, Zlotnik A, Vieira P, Mosmann T, Howard M, Moore K, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. *J Immunol*. 1991 May 15;146:3444–51.
208. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for Inflammatory Autoimmune Disease. *J Exp Med*. 1994;180:1961–6.
209. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. *Nat Immunol*. 2000 Dec;1:483–8.
210. Weetman A, McGregor A. Autoimmune thyroid disease: further developments in our understanding. *Endocr Rev*. 1994 Dec;15:788–830.
211. Lund FE. Cytokine-producing B lymphocytes—key regulators of immunity. *Curr Opin Immunol*. 2008;20:332–8.
212. Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review. *J Autoimmun*. Elsevier Ltd; 2014 Apr 30;10:1016.
213. Hammond L, Lowdell M, Cerrano P, Goode A, Bottazzo G, Mirakian R. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. *J Pathol*. 1997;182:138–44.
214. Flynn J, Conaway D, Cobbold S, Waldmann H, Kong Y. Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. *Cell Immunol*. 1989 Sep;122:377–90.

215. Stassi G, Zeuner A, Di Liberto D, Todaro M, Ricci-Vitiani L, De Maria R. Fas-FasL in Hashimoto's Thyroiditis. *J Clin Immunol*. 2001;21:19–23.
216. Peters P, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. *J Exp Med*. 1991 May 1;173:1099–109.
217. Mackenzie A, Schwartz A, Friedman E, Davies T. Intrathyroidal T Cell Clones from Patients with Autoimmune thyroid disease. *J Clin Endocrinol Metab*. 1987;64:818–24.
218. Wu Z, Podack E, McKenzie J, Olsen K, Zakarija M. Perforin expression by thyroid-infiltrating T cells in autoimmune thyroid disease. *Clin Exp Immunol*. 1994 Dec;98:470–7.
219. Ehlers M, Thiel A, Bernecker C, Porwol D, Papewalis C, Willenberg HS, et al. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto's thyroiditis. *J Clin Endocrinol Metab*. 2012 Apr;97:1347–54.
220. Ashkenazi A, Dixit V. Death receptors: signaling and modulation. *Science*. 1998 Aug 28;281:1305–8.
221. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al. Potential Involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. *Science*. 1997;275:960–4.
222. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tselenibalafouta S, Koutras D, et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. *J Clin Endocrinol Metab*. 1998;83:2199–203.
223. Borgerson K, Bretz J, Baker J. The Role of Fas-mediated apoptosis in Thyroid Autoimmune disease. *Autoimmunity*. 1999;30:251–64.
224. De Maria R, Testi R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. *Immunol Today*. 1998 Mar;19:121–5.
225. Kawakami A, Eguchi K, Tsuboi NM, Kawabe Y, Medicine I, Hospital NZ. Thyroid-Stimulating Inhibits Fas antigen-mediated apoptosis of human thyrocytes in Vitro. *Endocrinology*. 1996;137:3163–9.
226. Stassi G, Todaro M, Bucchieri F, Farina F, Zummo G, Maria R De, et al. Fas/Fas Ligand-Driven T Cell Apoptosis as a Consequence of Ineffective Thyroid Immunoprivilege in Hashimoto's Thyroiditis. *J Immunol*. 1999;162:263–7.
227. Bogner U, Schleusener H, Wall J. Antibody-Dependent Cell Mediated Cytotoxicity against Human Thyroid Cells in Hashimoto's Thyroiditis but Not Graves' Disease. *J Clin Endocrinol Metab*. 1984;59:734–8.
228. Guo J, Jaume JC, Rapoport B, McLachlan SM. Recombinant Thyroid Peroxidase-Specific Fab Converted to Immunoglobulin G (IgG) Molecules : Evidence for Thyroid Cell Damage by IgG1, but Not IgG4, Autoantibodies. *J Clin Endocrinol Metab*. 1997;82:925–31.
229. Weetman A, Bright-Thomas R, Freeman M. Regulation of interleukin-6 release by human thyrocytes. *J Endocrinol*. 1990 Nov;127:357–61.
230. Weetman A, Bennett G, Wong W. Thyroid follicular cells produce interleukin-8. *J Clin Endocrinol Metab*. 1992;75:328–30.
231. Nielsen CH, Brix TH, Leslie RGQ, Hegedüs L. A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. *Clin Immunol*. Elsevier Inc.; 2009 Nov;133:218–27.
232. Tomer Y. Anti-thyroglobulin Autoantibodies in Autoimmune Thyroid Diseases : Cross-Reactive or Pathogenic ? *Clin Immunol Immunopathol*. 1997;82:3–11.
233. Del Prete G, Tiri A, Mariottti S, Pincherat A, Ricci M, Cattedra R, et al. Enhanced production of  $\gamma$ -interferon by thyroid-derived T cell clones from patients with Hashimoto's thyroiditis. *Clin Exp Immunol*. 1987;69:323–31.
234. Ajjan R, Watson P, McIntosh R, Weetman A. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. *Clin Exp Immunol*. 1996 Sep;105:523–8.
235. Guo J, Rapoport B, McLachlan S. Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. *Autoimmunity*. 1999 Jan;30:1–9.
236. Colin I, Isaac J, Dupret P, Ledant T, D'Hautcourt J. Functional lymphocyte subset assessment of the Th1/Th2 profile in patients with autoimmune thyroiditis by flowcytometric analysis of peripheral lymphocytes. *J Biol Regul Homeost Agents*. 2004;18:72–6.
237. Weetman A. The potential immunological role of the thyroid cell in autoimmune thyroid disease. *Thyroid*. 1994;4:493–9.
238. Todd I, Pujol-Borrell R, Hammond L, Bottazzo G, Feldmann M. Interferon- $\gamma$  induces HLA-DR expression by thyroid epithelium. *Clin Exp Immunol*. 1985;61:265–73.
239. Marelli-berg FM, Weetman A, Frasca L, Deacock SJ, Imami N, Lombardi G, et al. Antigen Presentation by Epithelial Cells Induces Anergic Immunoregulatory CD45RO+ T cells and Deletion of CD45RA+ T cells. *J Immunol*. 1997;159:5853–61.
240. Ajjan R, Watson P, Weetman A. Ribonucleic Acid in the Thyroid of Patients with Autoimmune Thyroid Disease \*. *J Clin Endocrinol Metab*. 1997;82:666–9.
241. Kemp EH, Metcalfe RA, Smith KA, Woodroffe MN, Watson PF, Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. *Clin Endocrinol (Oxf)*. 2003;59:207–13.

242. Fiorentino D, Bond M, Mosmann T. TWO TYPES OF MOUSE T HELPER CELL IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. *J Exp Med*. 1989;170:2081–95.
243. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. *J Exp Med*. 1991;174:1209–20.
244. Chatila T, Silverman L, Miller R, Geha R. Mechanisms of T cell activation by the calcium ionophore ionomycin. *J Immunol*. 1989 Aug 15;143:1283–9.
245. Medzhitov R, Janeway CJ. Innate Immunity. *N Engl J Med*. 2000;343:338–44.
246. Jørgensen K, Skrede M, Cruciani V, Mikalsen S-O, Slipicevic A, Flørenes VA. Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. *Biochem Biophys Res Commun*. 2005 Apr 1;329:266–74.
247. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. *Nature*. 2000;406:782–7.
248. Assenmacher M, Löhning M, Radbruch A. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay. *Curr Protoc Immunol*. 2002 Feb;Chapter 6:Unit 6.27.
249. Wagner M, Rajasekaran A, Hanzel D, Mayor S, Rodriguez-Boulan E. Brefeldin A causes structural and functional alterations of the trans-Golgi network of MDCK cells. *J Cell Sci*. 1994 Apr;107:933–43.
250. Fujiwara T, Yokotas S, Takatsukig A, Ikeharan Y. Brefeldin A Causes Disassembly of the Golgi Complex and Accumulation of Secretory Proteins in the Endoplasmic Reticulum. *J Biol Chem*. 1988;263:18545–52.
251. Adorini L, Ullrich S, Appella E, Fuchs S. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells. *Nature*. 1990;346:63–6.
252. Yewdell J, Bennink J. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. *Science*. 1989 Jun 2;244:1072–5.
253. Liu S, Tobias R, McClure S, Styba G, Shi Q, Jackowski G. Removal of Endotoxin from Recombinant Protein Preparations. *Clin Biochem*. 1997;30:455–63.
254. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. *J Immunol*. 1999 Apr 1;162:3749–52.
255. Medzhitov R. Toll-like receptors and innate immunity. *Nat Rev Immunol*. 2001 Nov;1:135–45.
256. Chen L-Y, Zuraw BL, Zhao M, Liu F-T, Huang S, Pan ZK. Involvement of protein tyrosine kinase in Toll-like receptor 4-mediated NF-kappa B activation in human peripheral blood monocytes. *Am J Physiol Lung Cell Mol Physiol*. 2003 Apr;284:L607–L613.
257. Matsukawa A, Yoshinaga M. Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. *Inflamm Res*. 1998 Oct;47:S137–S144.
258. Mukherjee S, Chen L-Y, Papadimos TJ, Huang S, Zuraw BL, Pan ZK. Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. *J Biol Chem*. 2009 Oct 23;284:29391–8.
259. Byrne A, Reen D. Lipopolysaccharide Induces Rapid Production of IL-10 by Monocytes in the Presence of Apoptotic Neutrophils. *J Immunol*. 2002 Feb 15;168:1968–77.
260. Nielsen CH, Galdiers MP, Hedegaard CJ, Leslie RGQ. The self-antigen, thyroglobulin, induces antigen-experienced CD4+T cells from healthy donors to proliferate and promote production of the regulatory cytokine, interleukin-10, by monocytes. *Immunology*. 2009;129:291–9.
261. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. *J Immunol*. 2002 May 1;168:4531–7.
262. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes : inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. *Blood*. 2003;102:956–63.
263. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of toll-like receptors on B lymphocytes. *Cell Immunol*. 2005;236:140–5.
264. Shin H, Zhang Y, Jagannathan M, Hasturk H, Kantarci A, Liu H, et al. B cells from periodontal disease patients express surface Toll-like receptor 4. *J Leukoc Biol*. 2009 Apr;85:648–55.
265. Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel JT, Rubin D, et al. Toll-like receptors regulate B cell cytokine production in patients with diabetes. *Diabetologia*. 2010;53:1461–71.
266. Mita Y, Dobashi K, Endou K, Kawata T, Shimizu Y, Nakazawa T, et al. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4. *Immunol Lett*. 2002 Apr 1;81:71–5.
267. Ganley-leal LM, Liang Y, Jagannathan-bogdan M, Farraye F, Nikolajczyk BS. Differential regulation of TLR4 expression in human B cells and monocytes. *Mol Immunol*. 2010;48:82–8.
268. Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. *J Immunol*. 2009 Dec 1;183:7461–70.



269. Gray D, Gray M. What are regulatory B cells? *Eur J Immunol*. 2010 Oct;40:2677–9.
270. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. *Immunol Rev*. 2008 Aug;224:201–14.
271. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood*. 2003 Jun 1;101:4500–4.
272. Akira S, Takeda K, Kaisho T. Toll-like receptors : critical proteins linking innate and acquired immunity. *Nat Immunol*. 2001;2:675–80.
273. Klinker MW, Lundy SK. Multiple mechanisms of immune suppression by B lymphocytes. *Mol Med*. 2012 Jan;18:123–37.
274. Noh G, Lee JH. Regulatory B cells and allergic diseases. *Allergy Asthma Immunol Res*. 2011 Jul;3:168–77.
275. Dono M, Cerruti G, Zupo S. The CD5+ B-cell. *Int J Biochem Cell Biol*. 2004 Nov;36:2105–11.
276. Casali P, Notkins AL. PROBING THE HUMAN B-CELL REPERTOIRE WITH EBV : Polyreactive Antibodies and CD5+ B Lymphocytes. *Annu Rev Immunol*. 1989;7:513–35.
277. Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity. *Autoimmunity*. 2013;46:138–47.
278. Nielsen CH, Leslie RGQ, Jepsen BS, Kazatchkine MD, Kaveri S V, Fischer E. Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulinreactive CD4+ T cells in healthy individuals. *Eur J Immunol*. 2001;31:2660–8.
279. Schroeder K, Herrmann M, Winkler TH. The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. *Autoimmunity*. 2013 Mar;46:121–7.
280. McIntosh R, Watson P, Weetman A. Somatic hypermutation in autoimmune thyroid disease. *Immunol Rev*. 1998 Apr;162:219–31.
281. Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. *J Immunol*. 1991 Aug 15;147:1412–6.
282. Liu Y, Jones B, Aruffo A, Sullivan K, Linsley P, Janeway C. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. *J Exp Med*. 1992 Feb 1;175:437–45.
283. Hough M, Rosten P, Sexton T, Kay R, Humphries RK. Mapping of CD24 and homologous sequences to multiple chromosomal loci. *Genomics*. 1994;22:154–61.
284. De Souza AJ, Oriss TB, O'Malley KJ, Ray A, Kane LP. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. *Proc Natl Acad Sci U S A*. 2005 Nov 22;102:17113–8.
285. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. New roles for TIM family members in immune regulation. *Nat Rev Immunol*. 2008;8:577–80.
286. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. *J Clin Invest*. 2008;118:742–51.
287. Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, et al. Immunostimulatory Tim-1 – specific antibody deprograms Tregs and prevents transplant tolerance in mice. *J Clin Invest*. 2008;118:735–41.
288. Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. *Immunology*. 2006 Apr;117:548–57.
289. Amu S, Brisslert M. Phenotype and function of CD25-expressing B lymphocytes isolated from human umbilical cord blood. *Clin Dev Immunol*. 2011 Jan;2011:481948.
290. Amu S, Strömberg K, Bokarewa M, Tarkowski A, Brisslert M. CD25-expressing B-lymphocytes in rheumatic diseases. *Scand J Immunol*. 2007 Mar;65:182–91.
291. De Andrés C, Tejera-Alhambra M, Alonso B, Valor L, Teijeiro R, Ramos-Medina R, et al. New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids. *J Neuroimmunol*. Elsevier B.V.; 2014 May 15;270:37–44.
292. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. *Nat Immunol*. 2007 Dec;8:1353–62.
293. Griffin DO, Rothstein TL. Human “orchestrator” CD11b+ B1 cells spontaneously secrete IL-10 and regulate T cell activity. *Mol Med*. 2012 Jan;18:1003–8.
294. Hovsepian E, Penas F, Siffo S, Mirkin GA, Goren NB. IL-10 inhibits the NF-κB and ERK/MAPK-mediated production of pro-inflammatory mediators by up-regulation of SOCS-3 in *Trypanosoma cruzi*-infected cardiomyocytes. *PLoS One*. 2013 Jan;8:e79445.
295. Blackwell T, Christman J. The role of nuclear factor-kappa B in cytokine gene regulation. *Am J Respir Cell Mol Biol*. 1997 Jul;17:3–9.
296. Tak PP, Firestein GS. NF-κB : a key role in inflammatory diseases. *J Clin Invest*. 2001;107:7–11.
297. Lin W, Cerny D, Chua E, Duan K, Yi JTJ, Shadan NB, et al. Human Regulatory B Cells Combine Phenotypic and Genetic Hallmarks with a Distinct Differentiation Fate. *J Immunol*. 2014 Jul 30;193:2258–66.

298. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Annu Rev Immunol*. 2002 Jan;20:621–67.
299. Randolph G, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. *Curr Opin Immunol*. 2008;20:52–60.
300. Scala G, Oppenheim J. Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. *J Immunol*. 1983 Sep;131:1160–6.
301. Tosato G, Jones K. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. *Blood*. 1990;75:1305–10.
302. Beck L, Roth R, Spiegelberg H. Comparison of Monocytes and B Cells for Activation of Human T Helper Cell Subsets. *Clin Immunol Immunopathol*. 1996;78:56–60.
303. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B Lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. *J Immunol*. 1995;155:3734–41.
304. Rodríguez-Pinto D. B cells as antigen presenting cells. *Cell Immunol*. 2005 Dec;238:67–75.
305. Guo J, Wang Y, Rapoport B, McLachlan SM. Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II. *Clin Exp Immunol*. 2000;119:38–46.
306. Sundstedt A, Rosendahl A, Kalland T, Rooijen N Van, Dohlsten M. Immunoregulatory Role of IL-10 During Superantigen-Induced Hyporesponsiveness In Vivo. *J Immunol*. 1997;158:180–6.
307. Ding L, Linsley PS, Huang L, Shevach EM, Germain N. IL-10 Inhibits Macrophage Costimulatory Activity by Selectively Inhibiting the Upregulation of B7 Expression. *J Immunol*. 1993;151:1224–34.
308. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN. Impairment of regulatory T-cell function in autoimmune thyroid disease. *Thyroid*. 2013 Jul;23:871–8.
309. Pan D, Shin Y-H, Gopalakrishnan G, Hennessey J, De Groot LJ. Regulatory T cells in Graves' disease. *Clin Endocrinol (Oxf)*. 2009 Oct;71:587–93.
310. Marazuela M, Garcia-Lopez M, Figueroa-Vega N, de la Fuente H, Alvarado-Sanchez B, Monsivais-Urenda A, et al. Regulatory T Cells in Human Autoimmune Thyroid Disease. *J Clin Endocrinol Metab*. 2006;91:3639–46.
311. Nakano A, Watanabe M, Iida T, Kuroda S, Matsuzuka F, Miyauchi A, et al. Apoptosis-induced decrease of intrathyroidal CD4+CD25+ Regulatory T Cells in Autoimmune Thyroid Diseases. *Thyroid*. 2007;17:25–31.
312. McAleer JP, Liu B, Li Z, Ngoi S-M, Dai J, Oft M, et al. Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization. *J Leukoc Biol*. 2010 Jul;88:21–31.
313. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. *Proc Natl Acad Sci U S A*. 2007 Oct 23;104:17034–9.
314. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*. 2006 Feb;24:179–89.
315. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. *J Exp Med*. 2005 Apr 4;201:1061–7.
316. Yang XO, Pappu B, Nurieva R, Akimzhanov A, Soon H, Chung Y, et al. Th17 lineage differentiation is programmed by orphan nuclear receptors RORa and RORgamma. *Immunity*. 2008;28:29–39.
317. De Jong E, Suddason T, Lord G. Translational mini-review series on Th17 cells: development of mouse and human T helper 17 cells. *Clin Exp Immunol*. 2010 Feb;159:148–58.
318. Mane VP, Heuer MA, Hillyer P, Navarro MB, Rabin RL. Systematic method for determining an ideal housekeeping gene for real-time PCR analysis. *J Biomol Tech*. 2008 Dec;19:342–7.
319. Ryder LR, Woetmann A, Madsen HO, Ødum N, Ryder LP, Bliddal H, et al. Expression of full-length and splice forms of FoxP3 in rheumatoid arthritis. *Scand J Rheumatol*. 2010 Aug;39:279–86.
320. Nielsen CH, Hegedüs L, Leslie RGQ. Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. *Eur J Immunol*. 2004;34:263–72.
321. Nielsen CH, Moeller AC, Hegedüs L, Bendtzen K, Leslie RGQ. Self-Reactive CD4+ T Cells and B Cells in the Blood in Health and Autoimmune Disease: Increased Frequency of Thyroglobulin-Reactive Cells in Graves' Disease. *J Clin Immunol*. 2006;26:126–37.
322. Nielsen C, Hegedüs L, Rieneck K, Moeller A, Leslie R, Bendtzen K. Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. *Clin Exp Immunol*. 2007 Feb;147:287–95.
323. Weiss I, Davies TF. Inhibition of immunoglobulin-secreting cells by antithyroid drugs. *J Clin Endocrinol Metab*. 1981 Dec;53:1223–8.

324. Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Roesslein M, et al. Thionamides Inhibit the Transcription Factor Nuclear Factor-kappa B by Suppression of Rac1 and Inhibitor of kappaB Kinase alpha. *J Pharmacol Exp Ther*. 2008;324:1037–44.
325. Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. *Curr Pharm Des*. 2001 Apr;7:451–60.
326. Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev Y V, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. *Nat Med*. 2014 Jun;20:633–41.
327. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *Nature*. 2014 Mar 20;507:366–70.
328. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. *Ann Rheum Dis*. 2013 Apr;72:ii116–ii123.
329. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. *Ther Adv Musculoskelet Dis*. 2013 Jun;5:141–52.
330. Isono F, Fujita-Sato S, Ito S. Inhibiting RORyt/Th17 axis for autoimmune disorders. *Drug Discov Today*. 2014 Aug;19:1205–11.